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Abstract 
 
The aims of the current study were to investigate the effect of pressure on 
polyethyelene glycol (PEG4000) to create an effective drug delivery system for 
poorly water soluble drugs, with a view to increasing their bioavailability. The effect 
of pressure exerted by a diamond anvil cell on PEG4000 and the model drug 
respectively, and the polymer and drug together were examined using Raman and 
infrared spectroscopy. PEG4000 was shown to melt at 5GPa using a diamond anvil 
cell, as exemplified by flowing. Hydrocortisone does not melt under pressure or 
physically change and thus could be effectively encapsulated in the PEG at high 
pressure. Differential scanning calorimetry was carried out on the samples. PEG4000 
was observed to melt over an average range of 58.67 to 63ºC and hydrocortisone was 
observed to melt over an average range of 223.49 to 228.15ºC. The latter was 
observed to change from a white powder into a marigold yellow liquid. 
Thermogravimetric analysis revealed degradation occurred at temperatures distinct 
from the melting range, thus when PEG melts at high pressure it is not degrading. 
Drug release testing was carried out on the diamond anvil cell samples in simulated 
intestinal and gastric fluids over 8 hours in a pulsatile fashion, mimicking traditional 
cortisol replacement therapy but with one administration rather than multiple 
administrations daily. Scale up using a large volume press was investigated. Drug 
release occurred over 10 days in a similar pulsatile fashion to the small volume 
study. Unfortunately due to the highly unstable nature of hydrocortisone in aqueous 
solutions future work may require the use of stabilisers such as fructose or disodium 
edentate. Overall PEG does increase the solubility of poorly soluble drugs but further 
work could be carried out in terms of formulation. 
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Chapter 1: Introduction 
 
1.1 Basic Principles of Poorly Soluble Drugs 
Poorly water-soluble drugs cause a number of problems in drug delivery. Due to 
their inability to dissolve in the gastrointestinal fluids, they fail to be fully absorbed 
from the gastrointestinal tract. This can cause inadequate and irregular introduction 
of the drug into the systemic circulation, resulting in poor bioavailability (Blagden et 
al., 2007). Currently more than 40% of currently available drugs have this problem 
(Roberts and Zhang, 2013), including drugs such as griseofulvin, digoxin, phenytoin, 
sulphathiazole, hydrocortisone and chloramphenicol (Leuner and Dressman, 2000). 
70% of drugs being developed in recent years have exhibited poor solubility and thus 
the problem is on the rise (Ku and Dulin, 2012). This has been attributed to the 
increasing number of complex synthetic compounds being produced (Kawakami, 
2012). These drugs can be characterised by the Biopharmaceutical Classification 
System.  
 
In the Biopharmaceutical Classification System, drugs are categorised based on their 
ability to dissolve and be absorbed. These fall into Classes I, II, III and IV. Class I 
has hydrophilicity and lipophilicity, allowing dissolution and absorption. Class II 
drugs, or hydrophobic drugs, have a lack of dissolution capability but can be well 
absorbed. Class III drugs, have the ability to dissolve in the aqueous gastrointestinal 
fluid, but cannot be absorbed into the surrounding tissues. Class IV lack both 
dissolution capability and absorption capability. Class II drugs are a greater area of 
interest in oral drug development currently due to the fact they are inhibited by their 
inability to dissolve in the gastrointestinal fluid but, unlike Class IV, they can be 
absorbed once dissolution has been facilitated through formulation (Sant et al., 
2004).  
 
Poor solubility causes problems with patient compliance as it can necessitate greater 
volumes of drug to be administered or shorter dosage intervals (Roberts and Zhang, 
2013). This is required as the volume of drug entering the blood stream and thus the 
blood concentration of the drug needs to be sufficient to be within the therapeutic 
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index for reasonable pharmacology to occur. This can result in adverse effects due to 
the higher than normal dose present in the gastrointestinal tract (Kawabata et al., 
2011).  
 
1.2 Oral Drug Delivery of Poorly Soluble Drugs 
Drug release of hydrophobic agents commonly happens in the particle state, 
primarily by erosion and as such dissolution largely happens after release of drug 
particles into the gastrointestinal fluid (Tahara et al., 1996). Oral drug delivery is the 
preferred method of administering medication as it allows self administration and 
accurate dosing which makes it a cheaper and easier method of administration than 
other dosage forms (Vasconcelos et al., 2007). As such it is beneficial to improve the 
solubility of hydrophobic drugs to allow oral dosing with good bioavailability. The 
bioavailability of poorly soluble drugs contained in delivery formulation is 
dependent on the solubility evoked by the drug delivery system as the bioavailability 
of the drug alone is so poor (Pouton, 2006).  As such polymers are a major area of 
interest for drug delivery of poorly water-soluble drugs. 
 
Polymers are defined as substances consisting of macromolecules, which are 
constructed from a replicating pattern of smaller molecules, known as monomers, 
connected with covalent bonds (Jenkins et al., 1996). Polymers were discovered in 
the early 20th century due to the interest of scientists in the skill of nature to construct 
substances which were of use to humans, such as cotton, rubber and silk. Initially 
scientists believed these substances to consist of large structures made up of 
noncovalently clustered small molecules. However in 1920, Staudinger changed this 
view dramatically by stating his belief that covalently bonded high molecular weight 
molecules were in fact the main components of these substances and that this 
property was essential for the characteristics of the overall structure. Eventually 
6WDXGLQJHU¶V ZRUN LQWR V\QWKHWLF SRlymers earned him the 1953 Nobel Prize for 
Chemistry (Serpe and Craig, 2007). Synthetic polymers are now used more 
frequently than natural ones due to the increasing ability to mimic the properties of 
their natural counterparts and the ease and cost effectiveness of production in the lab.   
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Polymers can fall into a number of categories based on their components. A 
homopolymer is defined as one which consists solely of one type of monomer. A 
copolymer is one which is made up of multiple types of monomer. This latter 
category can also be described in terms of the number of monomer types, such as 
bipolymers for those consisting of two types, terpolymers for those consisting of 
three types and quaterpolymers for those consisting of four types. There can also be 
what is described as a pseudo-copolymer. Although this is like a homopolymer in 
that it consists of only one monomer type, it has a structure more similar to that of 
the copolymers due to the uneven nature of the macromolecules making up the 
individual monomers. Likewise they can be defined by the presence of particular 
types of macromolecules, such as block macromolecules, which can form part of 
block copolymers. A block macromolecule is defined as groups of many atoms 
working together, organised as structures known as blocks, which are covalently 
linked and configured in a linear formation (Jenkins et al., 1996).  
 
Structurally, polymers can also have a number of different architectures, such as 
linear, graft or brush, hyperbranched, star, block co-polymer and dendrimer (Figure 
1).  
A)                                                                      B)        
 
                                             
       C)                                                                          D)  
 
 
        E)                                                                    F) Block copolymer (eg. Linear, star)  
 
 
 
 
 
Figure 1: Polymer Architectures: A) Linear polymers, B) Graft polymers, C) Hyperbranched 
polymers, D) Star polymers, E) Dendrimer polymers and F) block copolymers  
Hydrophobic region 
Hydrophilic region 
Hydrophilic region 
Hydrophobic region 
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The form of a polymeric molecule can dictate its physicochemical properties, such as 
tolerance to varying pH and temperature, solubility, permeability and viscosity (Qui 
and Bae, 2006). Linear molecules are the most basic structure, consisting solely of 
chain with no branches (Jenkins et al., 1996). These have a number of advantages in 
that they can form random coils and the ability to effectively link drug molecules to 
the backbone (Qui and Bae, 2006). Polymers can also be branched in nature, as 
exhibited by a number of structures. A graft structure is made up of polymeric main 
chain with many polymer side-chains, creating a highly branched structure (Li et al., 
2013). Block co-polymers are described as structures with two or more sections in 
the backbone which can exhibit either solubility or insolubility. However these are 
less useful as their ability to move is limited (Qui and Bae, 2006). A hyperbranched 
structure consists of an unsystematically highly branched molecule, with a partially 
yielding globular configuration, which can covalently bind drugs to its surface 
(Kolhe et al., 2004, Kirkorian et al., 2012). A star structure exhibits hyperbranched 
character, consisting of linear arms radiating from a centre point. This central core 
can exhibit hydrophobic character while the arms tend to be hydrophilic making it 
useful to carry poorly soluble drugs (Qui and Bae, 2006). A dendrimer exhibits a 
three-dimensional structure consisting of branching units radiating out from a central 
point, within which a poorly soluble drug can be contained (Gillies and Fréchet, 
2005). Their dimensions can be determined by synthetic methods and other 
alterations can be used to increase biocompatibility and biodegradability 
(Suttiruengwong S. et al., 2006). The latter two forms are more efficient methods of 
transporting hydrophobic drugs as the drug is able to be encapsulated in the centre of 
the formulation surrounded by a hydrophilic polymer. However, these architectures 
are only one level of polymer organisation; a further level is observed in the 
structures they take at a higher level.  
 
Polymers can be used in a number of configurations to create oral formulations such 
as reservoir, microparticulate, nanoparticulate, micellular and polymer-drug 
conjugate forms. Reservoir based systems are also a widely used polymeric system. 
In this formulation type the active pharmaceutical ingredient is contained inside a 
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polymer barrier layer in the form of a film (Yang and Pierstorff, 2012). This form of 
system is most commonly used as part of an injectable dosage form or slightly less 
commonly as part of an implant, however there is recent research into its use orally 
(Figure 2). Alza Corporation introduced a reservoir oral osmotic dosage form known 
as OROS®. It consists of a capsule coated with an unyielding semi-permeable 
membrane with a 0.5-1.4mm laser-drilled hole. Following swallowing, the aqueous 
gastrointestinal fluid passes through the semi-permeable membrane into the reservoir 
and the active ingredient leaves the system through the drilled hole as the osmotically 
active polymers swell (Stevenson et al., 2012). This could potentially be used to 
improve delivery of poorly soluble drugs. 
Delivery of poorly soluble drugs can also be significantly improved through the use 
of polymeric nanoparticles and microparticles. The solubility increase in both of 
these can be greatly attributed to the increase in surface area generated by the 
reduced particle size (Lee et al., 2010, Kumar et al., 2011). In nano and 
microparticulate systems the drug can be dispersed throughout the polymer during 
production of the particles or absorbed on to the surface of the particles by dipping 
the particles into a concentrated solution of drug (Agnihotri et al., 2004). The active 
pharmaceutical ingredient can be covalently bound to either type of particle. 
Nanoparticles are defined as being systems which are largely used at a size range of 
3-200 nm, and have the advantage of being able to be altered in size to change rates 
of release and thus delivery times of drugs (Cho et al., 2008).  Nanoparticles can be 
subdivided into nanocapsules and nanospheres (Figure 3).  
A)                                                                         B)  
 
 
 
 
 
Figure 2: Examples of reservoir systems include A) L-OROS and B) Tri-layer capsules 
(Stevenson et al., 2012) 
Delivery orifice 
Rate-controlling 
membrane 
Drug compartment 
1 
Drug compartment 2 
Drug compartment 3 
Drug overcoat 
Delivery orifice 
Rate-controlling membrane 
Osmotic push layer  
Barrier inner membrane 
Soft gelatine capsule 
Liquid drug formulation 
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Nanocapsules (Figure 3A) are vesicle like structures which consist of a polymer 
layer encapsulating a central hollow where the drug is contained. In nanospheres 
however the drug is scattered throughout a polymer matrix (Figure 3D) (Soppimath 
et al., 2001). Nanoparticles should have a net hydrophilic character to allow efficient 
transport of the drug, which can be achieved through a hydrophilic surface coating, 
with a polymer such as polyethylene glycol, or using block copolymers with a 
combination of hydrophobic and hydrophilic properties but the latter having the 
greatest influence. Examples of polymeric nanoparticle systems include polyglycolic 
acid (PGA) for use in delivery of camptothecin and N-(2-hydroxylpropyl) 
methacrylamide (HPMA) for delivery of doxorubicin (Cho et al., 2008). 
A)                                                         B)                                     C) 
 
 
 
 
D)                                                                                      E) 
                                                              
                                                           F) 
 
 
 
 
G)                                                                                         H) 
 
 
Figure 3: Micro and nanoparticle structures: A) capsule, B) solid particle, C) solid 
particle with polymeric extensions, D) solid particle with the drug dispersed, E) solid 
particle entrapping a drug, F) solid particle with the drug adsorbed to the surface, G) 
capsule with the drug adsorbed to the surface and H) a capsule containing a drug at 
its core  
Drug 
Polymeric 
capsule  
Polymeric 
extensions 
Drug 
entrapped 
in solid 
particle 
Drug adsorbed 
to solid particle 
Drug 
adsorbed to 
capsule 
surface 
Drug 
encapsulated 
Drug dispersed throughout 
the particle 
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Microspheres preferably have a particle size lower than 200ʅm, ranging in 
dimensions from 0.1-200ʅm (Madhav and Kala, 2011). Microcapsules have a similar 
structure to nanocapsules. Microcapsules can have one cavity, known as monocored 
microcapsules, or more than one cavity, known as polycored microcapsules. They 
can also have the drug incorporated into the polymeric layer, known as matrix type 
polymeric microcapsules. As with nanospheres, microspheres exhibit a structure 
which consists of the active pharmaceutical ingredient being scattered throughout a 
polymer matrix (Figure 3E). Very different release profiles can be observed in these 
compared with microcapsules due to their different structures (Kumar et al., 2011). 
Examples of poorly soluble drugs which can be effectively carried in microparticles 
include paclitaxel, aclacinomycin and camptothecin (Takale et al., 2012). 
 
Polymeric micelles are useful as another method of delivering a number of drugs 
(Figure 4). The dosing method is made up of an outer water-soluble layer, 
surrounding a drug and excipient-based hydrophobic centre, which makes it a highly 
suitable system for delivery of poorly-soluble drugs (Kim et al., 2009, Kim et al., 
2011). Hydrophobic splinters of amphiphilic molecules are found within the central 
cavity of a micelle, which can be used to increase the solubility of hydrophobic 
drugs. Hydrophilic polymers such as polyethylene glycol are used to form the outer 
layer of the micelle, while hydrophobic polymers, such as those consisting of 
propylene oxide, aspartic acid and spermine monomers, are used to form the central 
cavity in which poorly soluble drugs can be encapsulated (Torchilin, 2004). Many 
polymers have been used to construct self-assembled micelles, the majority of which 
are linear block copolymers. These have main chains consisting of polymers such as 
polyethylene glycol, poly(N-vinyl-2-pyrrolidone) and poly(vinyl alcohol), with 
hydrophobic sections consisting of polymers such as polyester and poly(amino acid)s 
(Guo et al., 2012). An example of micelles used for hydrophobic drugs is detailed in 
a recent study where the solubility of the poorly soluble anti-cancer agent paclitaxel 
was improved by encapsulation in a water-soluble polymeric micelle system based 
on poly(2-(4-(vinylbenzyloxyl)-N,Ndiethylnicotinamide)and polyethylene glycol 
block copolymers (Huh et al., 2005). Examples of other poorly soluble agents which 
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have shown improved solubility and delivery capacity on micellation include 
diazepam, indomethacin, adriamicin and polynucleotides (Torchilin, 2004). 
 
Polymer-drug conjugates are another effective method of delivering poorly soluble 
drugs (Figure 5). Generally the conjugated form is a prodrug, which, via acid/base 
hydrolysis or enzyme cleavage, can release the original drug when required (Kim et 
al., 2009). The active pharmaceutical ingredient can be attached straight on to a 
polymeric backbone or indirectly so through a linker, which may or may not be able 
to be broken down in the body. The polymeric backbone majorly affects the 
pharmacokinetics and pharmacodynamics of the agent and thus it imparts solubility 
on the hydrophobic drug (Markovsky et al., 2012). A significant example of this is 
the use of polyethylene glycol in conjunction with a chemotherapeutic polypeptide 
molecule as a potential cancer treatment such as PEG-IFN-ɲ (Fox et al., 2009, 
Narang and Varia, 2011).  
Figure 5: Basic structure of a polymer-drug conjugate, consisting of a polymer backbone in 
purple, a linker group in blue and a drug molecule in green 
Figure 4: Structure of micelles, with the drug in green encased in a central core 
surrounded by hydrophobic blocks in purple and hydrophilic blocks represented by 
the lines extending from these purple blocks.  
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Polymers used for oral drug delivery of poorly soluble agents can also be divided up 
into a number of types at a further level of structural integrity. This level of structure 
includes diffusion-controlled systems, solvent-activated systems, chemically 
controlled systems and magnetically controlled systems. The former can be either in 
the form of reservoir systems (Figure 2) or matrix systems (Figure 6). However due 
to the risk of rupture and resultant dose dumping, matrix systems are preferred as the 
drug is evenly distributed throughout the medium and thus the drug is released at a 
more constant rate.  
Figure 6: Matrix structure with drug evenly distributed throughout the tablet in green 
 
A) 
 
 
B) 
 
 
 
 
 
 
Figure 7: Solvent Activated Systems can be divided into A) Osmotically-controlled 
and B) Swelling-controlled models. In A) it can be observed that the gastric fluid 
(shown as blue arrows) forces the drug out of a hole in the tablet surface, and in B) 
it can be observed gastric fluid is absorbed, causing the system to swell and become 
permeable to drug release.  
GIT Fluid 
absorption 
GIT Fluid 
absorption 
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Solvent-activated systems can be divided into osmotically controlled systems and 
swelling-controlled systems (Figure 7). In the former, the gastrointestinal fluid 
moves from a low concentration of drug out with the system to a high concentration 
of drug inside the system. The increased fluid inside the system forces the drug out 
of a crack in the system. In swelling-controlled systems, the  
polymer absorbs water, becoming turgid without dissolving in the fluid. The system 
exhibits permeability which allows the drug to be released through the swollen 
polymer layer. Magnetically controlled systems are made up of albumin and 
magnetic microspheres, which give the system a targeting capacity which is useful in 
cancer chemotherapy.  
Release of the drug is triggered by a magnetic field (Figure 8). Chemically controlled 
V\VWHPV FDQ DOVR EH FDWHJRULVHG LQWR ³SHQGHQW-FKDLQ´ V\VWHPV DQG ELRGHJUDGDEOH
systems (Figure 9). The former involves the drug being chemically linked to the 
polymer backbone, and drug release happens via chemical hydrolysis or enzymatic 
degradation. In the latter, like the matrix systems the drug is distributed throughout 
the system and as the polymer breaks down by erosion the drug is gradually released. 
Due to the fact, unlike some polymer systems (.RSHþHk, 1990), this form breaks 
down in the gastrointestinal fluid and does not need to be removed from the body due 
to potential toxicity and has been shown in the past to be the most effective for 
delivery of poorly soluble drugs this is very likely to be the main type of system used 
for this purpose in the future (Ranade and Hollinger, 2004).  
Figure 8: A magnetic field triggers drug release from magnetically controlled 
systems with the drug illustrated in green and the controlling membrane in purple. 
Activation by 
magnetic field  
Release of drug  
Drug 
reservoir 
Magnetic 
membrane 
14 
 
 
1.3 Polyethylene Glycol 
The current study will use the well established hydrophilic polymer polyethylene 
glycol (PEG, see Figure 10) as a medium for creating a drug delivery system to 
increase the water solubility of poorly water soluble drugs. PEG has a number of 
advantages as a currently used excipient and as such is the polymer which is most 
commonly incorporated into drug delivery systems. These largely include the fact it 
has been deemed clinically safe, it is not costly to manufacture and it can behave in a 
stealth-like manner, allowing it to pass through the body without being regarded as 
foreign by the immune system (Knop et al., 2010).  
 
Polyethylene glycols (PEG) are made up of ethylene oxide monomers (Figure 10) 
and usually have molecular weights around 200-300,000g/mol. In the context of 
delivery systems polyethylene glycol is generally applied at molecular weights of 
H 
H O 
O 
n 
Figure 10: Chemical structure of polyethylene glycol 
A)                                                                  
                                                                              Polymer Backbone 
 
                                                                                  
                                                       Drug       
                                                                      Cracks in system surface developing 
                              
 
B)  
 
                              Polymer Matrix                               Complete degradation of the system 
Figure 9: Chemically Controlled Systems fall into two categories A) Pendant chain 
systems and B) Biodegradable systems 
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1,500-20,000g/mol. The greater the molecular weight the greater the thickness of the 
SRO\PHU¶Vconsistency, which can be a key determinant in the rate of drug release as 
their solubility is inversely proportional to molecular weight (Leuner and Dressman, 
2000). Largely the melting points of polyethylene glycols are less than 65°C, making 
them suitable for production of delivery systems using melt techniques. For example 
PEG 1000 has a melting point of 30-40°C, while PEG 20,000 has a melting point of 
60-63°C (Price et al., 1994). Ideally for drug incorporation the polyethylene glycol 
should have a molecular weight that is high enough to impart sufficient water 
solubility on to the drug without having the issue of water being absorbed and held in 
the medium and a melting point above 50°C. If a polyethylene glycol with too small 
a molecular weight is applied, the polymer can exhibit a gummy texture making it 
difficult to create a suitable formulation. However higher molecular weights have 
proved more successful in increasing solubility of hydrophobic drugs (Leuner and 
Dressman, 2000, Li and Jasti, 2005).  
 
It has been shown that the ability of PEG to increase solubility is so great that even 
quite a soluble agent like aspirin can have its ability to dissolve improved still further 
by incorporation into polyethylene glycol 6000 (Asker and Whitworth, 1975).  In 
their matrix form they are broken down from the outside in and usually do not puff 
up or crumble in water-based media, allowing drug release can be regulated 
relatively simply. It can be used to increase the solubility of hydrophobic drugs 
because its water soluble polymeric chain has a wide hydrodynamic radius in water-
based media, enhancing hydrophilicity (Li and Jasti, 2005).   There are a number of 
examples of using polyethylene glycol to increase water solubility. 
 
The use of polyethylene glycol to improve the solubility of griseofulvin, which is a 
virtually insoluble drug and useful oral antifungal agent, has been well studied. In an 
early study incorporation of the drug into solid dispersions with PEG 4000, 6000 and 
20,000, was shown to significantly increase drug release and thus dissolution in the 
gastrointestinal fluids (Chiou and Riegelman, 1969). Gris-PEG is a commercially 
available griseofulvin preparation which has been released in recent years using PEG 
6000 and has been used clinically to great success (Janssens and Van Den Mooter, 
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2009). In combination with polysorbate 80, PEG 3350, was shown to enhance the 
bioavailability of a poorly water soluble drug 21-fold relative to the drug alone (Joshi 
et al., 2004). As mentioned previously dendritic and star polymer architectures form 
the best carrier structures for hydrophobic drugs. In the context of polyethylene 
glycol a recent study has shown the poorly soluble anticancer agent paclitaxel and 
other hydrophobic drugs are solubilised most effectively using these structures (Ooya 
et al, 2003).  
 
In the current study PEG4000, which has an estimated melting point of 58-61°C, has 
been selected as a polymer to increase the solubility of poorly soluble drugs. It was 
shown previously to increase the solubility of the poorly soluble drug Zolpidem® 
from 0.25mg/ml in a pure drug sample to 1.65mg/ml in a 30:70 PEG:drug solid 
dispersion (Trapani et al., 1999). Due to this efficiency it is thought PEG4000 will 
make a suitable polymer to solubilise the model drug in this study. 
 
1.4 The Model Drug 
 
Figure 11: Chemical structure of hydrocortisone 
 
Hydrocortisone (Figure 11) is classified in the British Pharmacopoeia as only slightly 
soluble in water (0.002M approximately as found by Foroutan and Watson, 1997) 
and thus is suitable to demonstrate the ability of polyethylene glycol to increase 
solubility. Hydrocortisone can be used for treatment of acute adrenal insufficiency, 
chronic primary adrenal insufficiency, secondary adrenal insufficiency and 
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congenital adrenal hyperplasia. As an extension of this it can also be used for 
management of rheumatic disorders, kidney conditions, asthma, allergies and other 
inflammatory conditions (Abad-Santos et al., 2002) as cortisol is vital for 
intermediate metabolism, the immune system and the muscular-skeletal system 
(Johannsson et al., 2009). It has also been suggested as a method of treating the 
depression and anxiety occasionally associated with smoking cessation as there is a 
marked fall in cortisol in individuals who have given up smoking (Ussher et al., 
2011). However its primary use is for issues either at an adrenal or pituitary level. 
 
Adrenal impairment can be caused by primary adrenal malfunction due to 
autoimmune disease or tuberculosis effects, or as a side effect of adrenal gland 
removal (Simon et al., 2010). Central reduction in cortisol can also occur as a result 
of reduced action of the pituitary gland, for example due to tumour growth 
(Johannson et al., 2009).  As a result of this hydrocortisone seeks to mimic natural 
cortisol release. 
 
Naturally the hypothalamus, mediated by the paraventricular nucleus, would excretes 
a hormone which would trigger release of corticotrophin from the pituitary, which in 
turn stimulates release of cortisol from the adrenal glands (Johannsson et al., 2007). 
Once the cortisol reaches a certain level it exerts negative feedback upon the 
hypothalamus and pituitary to prevent excess release and development of conditions 
such as adrenal hyperplasia and excessive testosterone secreation. 
 
One major risk of the use of hydrocortisone as a glucocorticoid replacement therapy 
is hypercortisolism, which results in reduced glucose tolerance and development of 
insulin resistance. Oral drug delivery has been suggested for hydorocortisone as it 
does not raise insulin resistance or reduce glucose tolerance as much as a typical 
parenteral dose regimen (McConell et al., 2002).  
 
There is much debate about the preferable dose for oral use as cortisol is released 
naturally on a circadian rhythm with the greatest release occurring on waking and 
decreasing over time until it reaches its minimum around midnight (Johannsson et 
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al., 2007). As such a dose regimen of hydrocortisone should try to mimic this as far 
as possible whether taking the form of a controlled release model or involving 
multiple dosing. The estimated volume of cortisol released in each individual can 
vary between approximately 10 and 30mg daily (Abad-Santos et al., 2002). This can 
vary as a result of genetics as well as stress factors such as exercise, fever, surgery 
or, mental or emotional stress (Johannsson et al., 2007). Some papers suggest a 30mg 
dose as standard (Abad-Santos et al., 2002) however some other literature suggests 
lower doses. For example McConell et al. suggest 15mg in the morning and 5mg in 
the evening as this lower dose was observed to result in less insulin resistance in 
patients (McConell et al., 2002). Simon et al. (2010) also suggest a 25mg dose, with 
around 66% being administered in the morning and around 33% in the afternoon. 
This will be taken in to account in the current study. 
 
1.5 High Pressure Phase Transformation 
There is increasing interest in exposure of polymers to high pressure conditions 
(Xiong and Kiran, 1998). High pressure can be utilised to bring about a large variety 
of alterations to the structure of soft material substances, from generating phase 
transformations in polymers to inducing formation and breakdown of tertiary 
structures in proteins (Brooks et al., 2010). This study is concerned with the phase 
transformation of polymers which is associated with polymorphism. Polymorphism 
is a term which originates from the Greek for being present as numerous different 
structures. In the context of chemistry and by extension pharmaceutical sciences, 
polymorphism largely refers to the different crystalline forms a substance can take. 
Each polymorph of a substance can have very different properties such as melting 
points, dissolution rate, stability, solubility and density. In the context of 
SKDUPDFHXWLFDOV WKHVHSURSHUWLHVFDQKDYHVLJQLILFDQWHIIHFWVRQGUXJV¶DELOLW\WREH
absorbed, their bioavailability in the body and formulation of effective drug delivery 
systems to carry them (Fabbiani and Pulham, 2006). In the context of the current 
study the ideal polymorph for use in a delivery system should possess sufficient 
water solubility to allow the drug to dissolve and thus should be a less stable 
polymorph. Solubility is determined by the form the substance takes, because 
different states of the substance will have distinct energies and thus distinct 
19 
 
solubilities. As an extension of this it can result different bioavailabilities evoked on 
the encased drug (Threlfall, 1995).  
 
High pressure still continues to be an underused method of inducing phase 
transformation because of its technical intricacy (Brooks et al., 2010). However it is 
a growing field. For example high pressure can result in production of a number of 
different polymorphs from the one original molecule. For example high-pressure 
recrystallisation of aqueous and methanolic solutions of piracetam (2-oxo-
pyrrolidineacetamide) can be carried out in a diamond avil cell at 0.07±0.4 GPa 
resulting in the production of a novel polymorph of piracetam. Reduction in pressure 
once more to ambient conditions can result in the generation of a further form via a 
single-crystal to single-crystal transition (Fabbiani et al., 2005).  
 
Molecular compounds generally stay intact at high pressure. For example Funnell et 
al. (2011) observed that pressure does not have much of an effect on alanine until it 
reaches 13.6 GPa. At 15.46 it goes through a phase change from a crystalline to an 
amorphous state, which, unlike some phase changes, is reversible (Funnell et al., 
2011). Another example of high pressure work is the polymerisation of lactide in 
which the room temperature crystalline state is constant until 17.3 GPa at 26.85°C 
(Ceppatelli et al., 2011). Polymers also have been previously studied at high pressure 
(Fang and Kiran, 2006). 
 
The application of pressure can directly influence the properties of polymers as 
exemplified in a number of studies. For example via X-ray diffraction and 
differential scanning calorimetry, the crystalline character of low density 
polyethylene was observed to be enhanced from 42 to 58% when placed under 
800MPa using hydrostatic high pressure processing for 5 minutes at 75ºC, and the 
crystalline character of PETA1Ox was raised from 28.5 to 36.3% to induce 
hydrostatic pressures of 500MPa for 15 minutes at 50ºC (Fleckenstein et al., 2013).  
In another study, on exposure to high pressure between 7 to 50MPa, the polymer 
syndiotactic polystyrene undergoes a liquid-liquid phase separation and forms a 
range of different crystalline structures (Fang and Kiran, 2009). In a further study, 
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isotactic poly (4-methyl-1-pentene) in n-pentane and, n-pentane and carbon dioxide 
mixtures was found to phase separate at pressures between 10 and 50MPa. Three 
different polymorphological changes were observed involving solid-solid phase 
transitions, resulting in a tightly packed crystalline structure formed at the higher end 
of the pressure range. On addition of carbon dioxide to isotactic poly (4-methyl-1-
pentene) a more hollow structure was observed (Fang and Kiran, 2006).  
 
The importance of pressure to the melting points of homo and copolymers such as 
HDPE, LDPE, PP and ethylene vinyl acetate have also been studied up to 330MPa 
using nitrogen atmospheric pressure and a high pressure differential thermal analysis 
cell. It was found the melting point rises proportionally to the pressure induced on 
the polymers (Seeger et al., 2004). In a further study using high pressure, the water 
uptake and turgor of poly(N-isopropylacrylamide) and poly(N-iso-
propylacrylamide)-poly(N,N-diethylacrylamide) originated microgels were 
investigated at high pressure and it was found the turgid state was preferable at high 
pressure to the deflated state (Pühse et al., 2010).  
 
A previous high pressure study of polyethylene glycol largely focused on the effect 
of vapour pressure induced by countercurrent circulation system RQ WKH SRO\PHU¶V
ability to solubilise in carbon dioxide. This study showed it can cause a fall in 
solubility in proportion to molecular weight (Daneshvar et al., 1990). This may be 
promising evidence for the current study. 
 
Methods of producing a high pressure environment include distortable diaphragms 
and rupture disks, pistons and dual cell designs (Xiong and Kiran, 1998). However in 
recent years most investigations in to phase transformation has been studied using 
diamond anvil cell (Zarechnyy et al., 2012, Feng et al., 2013). In the current study a 
Merrill-Bassett model will be used, as it has the advantage of inducing a pressure 
increase and maintaining it using three screws over the formerly used push method 
(Merrill and Bassett, 1974). This will be detailed further in chapter 2 of this study.  
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1.6 Aims and Objectives 
The aims of the study are to investigate the effect of pressure on polyethyelene 
glycol to create an effective drug delivery system for poorly water soluble drugs, 
with a view to increase their bioavailability. The objectives of the study are to study 
PEG under high pressure conditions using Raman spectroscopy, and to subject a 
mixture of poorly soluble drug and PEG to high pressure conditions with the view to 
generating a drug delivery system capable of releasing the drug in an efficient 
manner. 
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Chapter 2: Materials and Methods 
2.1 Materials 
The polyethylene glycol 4000 (batch number LOT#BCBG1709V) and 
hydrocortisone (batch number LOT#SLBD0859V) used were obtained from Sigma-
Aldrich (St Louis, Missouri, U.S.A). A drug-polymer mix can be achieved by placing 
a sample to the total mass of 500mg in a ball mill chamber (Serial number MM400, 
obtained from Retsch GmbH, Hann, Germany) with 2 metal balls, and shaking the 
sample for 30 mins at a frequency of 30Hz. Samples of the hydrocortisone to PEG 
ratios of 10:90, 20:80 and 50:50 were produced for the current study.  
 
2.2 Apparatus 
High pressure studies were carried out using a diamond anvil cell obtained from 
High Pressure Diamond Optics Ltd. (Tucson, Arizona, U.S.A) with gaskets drilled 
using a Boehler microdriller obtained from Almax EasyLab Group Ltd. (Cambridge, 
Massachusetts, U.S.A.) with a 0.25mm tungsten carbide rod drill piece. Samples 
were photographed using a Reichert Polyvar-Met Microscope (obtained from 
Depew, New York, U.S.A.) Raman spectroscopy was carried out using a Thermo 
Scientific DXR Raman Microscope (serial number AIY100276) with a 532nm laser 
obtained from Thermo Fisher Scientific (Waltham, Massachusetts, U.S.A.). Infrared 
Spectroscopy was carried out using a Thermo Scientific Nicolet ISIO Infrared 
Spectrometer was also obtained from Thermo Fisher Scientific (Waltham, 
Massachusetts, U.S.A.). Differential Scanning Calorimetry was carried out using a 
Metler Toledo Differential Scanning Calorimeter (DSC 822e/400Ro, serial number 
5125178759). Thermogravimetric analysis was carried out using a Metler Toledo 
Thermogravimetric Analyzer (TGA/SDTA851e/LG/Ro, serial number 5125178760). 
These were both obtained from Metler Toledo Ltd. (Leicester, U.K.). Drug release 
was analysed using a Dionex High Performance Liquid Chromatography machine 
(PS80IPE, serial number 1190002) with Chromeleon Data Software obtained from 
Dionex (Cheshire, U.K.). 
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2.3 Techniques 
 
 
 
The diamond anvil cell (Figure 12) is a useful apparatus for investigating the effect 
of pressure on the physical properties of substances (Liu et al., 2011). This apparatus 
was introduced in 1958 and caused what has grown to be thought of as one of the 
greatest advances in the field of high-pressure study as it has delivered the greatest 
level of pressure ever triggered in a laboratory environment. The basis for the 
WHFKQLTXHZDVRULJLQDOO\ LQVSLUHGE\3:%ULGJPDQ¶VZRUNZLWK FDUEROR\XVLQJD
similar anvil structure in 1937(Katrusiak, 2008). However diamond was the crucial 
component for generating the required level of pressure, which was suggested in a 
study into high pressure X-ray diffraction 13 years later (Lawson and Tang, 1950). 
Diamond was not actually recorded as being used part of an anvil cell until 9 years 
later as part of another X-ray diffraction study (Jamieson et al., 1959) and that same 
Gasket 
Diamonds with 
cutlets facing each 
other 
Gasket hole 
forming a 
sample chamber 
Figure 12: The photographs above portray the exterior of a Merrill-Basset 
diamond anvil cell, the diagram below them illustrates the orientation of the 
diamonds and the gasket within. 
Sample chamber generated by 
gasket hole on surface of diamond 
Metal frame 
Backing 
disk 
Screws which 
can be used to 
increase pressure 
Diamond 
surface 
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year as part of an infrared study using diamond anvil cell to create sufficient pressure 
to allow analysis of CO3 ions (Weir et al, 1959). Jamieson et al. used a clamped right 
angle arrangement, while Weir et al. used a horizontal configuration (180º) and a 
spring loaded lever arm. Both the features of the latter study have since become 
common place in diamond anvil cell apparatus (Jayaraman, 1983). The diamond 
anvil cell method was developed further with the introduction of the use of a metal 
gasket to allow creation of a sample chamber and the development of hydrostatic 
pressure techniques, by encasing aqueous solutions (Valkenburg, 1962). Possibly the 
greatest advance in the use of the apparatus was the introduction of a way to calibrate 
the device in the form of ruby-florescence spectroscopy (Forman et al, 1972), as 
prior to this there was no accurate method of knowing the exact pressure applied to a 
substance in the cell (Piermarini and Block, 1975). 
 
The principle of the use diamond anvil cell is that by employing moderate axial 
forces to the region between the points of two diamonds, high pressures can be 
generated. As one of the hardest substances on earth, diamonds have the power to 
bear such forces where other substances would fail (Taylor and Pasternak, 1990). 
The use of diamond also has a number of other advantages including little absorption 
of short X-rays, its transparency is useful for both visual radiation and analysis using 
UV, IR and Raman spectrophotometry (Katrusiak, 2008).  
 
The diamond anvil cell creates a pressurised environment when the substance tested 
is added to a central cavity and the hydrostatic fluid is enclosed and compressed 
between the diamond tips and the distorted gasket. The pressure generated is highly 
dependent on the size and shape of the diamond points and the gasket (Katrusiak, 
2008).  This follows the connection between force and area, and pressure (P=F/A), 
showing that the greater the force applied to the smaller the area, the greater the 
pressure generated. Thus the cutlets of the diamonds normally have a diameter of 
around 1mm, giving a surface area of around 0.8mm2 (Smith and Fang, 2009). The 
force evoked upon the diamonds is controlled by one of two methods, either using 
screws or a gas membrane. In the former, the energy evoked is generated by 
tightening screws directly into the apparatus itself or via an arrangement of levers. 
25 
 
The latter generates the required energy by altering the pressure of a gas loading a 
metallic membrane that thrusts the two halves of the apparatus together. As a whole 
the screw method is the more straightforward of the two and is therefore more 
consistent, they can sustain the pressure for longer and they have more predictable 
effects in response to temperature. As such that is the method which will be applied 
in the current study (Kantor et al., 2012).   
 
Studies over the years have allowed more and more applications to be discovered, 
including extensive investigations in to the effects of temperature and pressure on 
various substances, such as phase transitions, visual effects with polarized light, Xray 
crystallography and Raman spectroscopic investigations (Piermarini and Block, 
1975). It has also allowed complex investigations on microscopic materials and other 
previously very difficult procedures to become standard practices (Jayaraman, 1983). 
In the context of polymers diamond anvil cell has allowed analysis of 
depolymerisation, decomposition, liquefaction, degradation and decholination. 
Condensation polymers including polyethylene terephthalate and nylon are fully 
solubilised in aqueous solutions at elevated temperatures initiated by the anvil cell, 
whereas addition polymers such as polystyrene break down in a heterogeneous 
manner in the aqueous solution (Smith and Fang, 2009). In a previous study 
polyethylene terephthalate was found to crystallize at high temperatures, due to the 
development and supersaturation of oligomers of terephthalic acid, with a greater 
temperature of dissolution (Fang et al., 1999). Due to the fact polyethylene glycol 
also undergoes condensation polymerisation, perhaps polyethylene glycol would 
behave in a similar manner to polyethylene terephthalate. Other evidence for this 
type of study can be seen in the work of Oswald and Urquart (2011). They studied 
the polymorphism of acrylic acid and methacrylic acid using diamond anvil cell to 
induce a high pressure polymer. Using Raman spectroscopy the crystallisation 
pressures for each of the two polymorphs were found to be 0.65GPa and 1.5GPa 
respectively before compression to induce polymerisation without the use of heat or 
initiators (Oswald and Urquhart, 2011). In another study by Oswald and Urquhart in 
collaboration with Johnston, Marshall and Parsons (2014) acrylic acid was found to 
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go through a phase change at 0.8GPa and stay intact in that molecular state until 
7.2GPa, but it polymerized on complete removal of pressure.   
 
Due to the fact that some polymorphs possess higher melting points, phase transition 
can require heating. Due to its relatively inert nature diamond can withstand high 
temperatures and as such diamond anvil cell is highly useful for determination of 
phase transformations at high temperatures. For example nylon has been found in a 
previous study to entirely dissolve in water at 331°C (Smith and Fang, 2009). 
Another example is a diamond anvil cell study which featured heating of 
polyethylene causing phase transformation. This could be observed in the transition 
into the liquid phase on a quick increase in temperature, followed by turgidity and 
colour changes above 450ºC and 570ºC respectively (Fang et al., 2000). Creating a 
melt can result in phase changes which could not occur from the solid state alone 
(Oswald and Urquart, 2011). All of the properties of the polymorphs can be analysed 
via a selection of methods.  
 
2.4 Methods 
 
2.4.1 Diamond Anvil Cell 
Initially a tungsten gasket was indented using the diamond cutlets by increasing the 
pressure on the gasket by tightening the screws until an indent of between 80 and 
120ʅm could be measured and observed through a microscope. This is to support the 
tip of the diamond which experiences very high pressures. A pilot hole was drilled, 
using an Almax Easylab gasket drill, to the depth of 100ʅm at a site distinct from the 
indent to aid alignment of the instrument. The eye piece was then centred to the pilot 
hole and the indent lined up to the eyepiece. A hole was drilled through the indented 
gasket. It was ensured the hole was cleanly cut using a microscope and removing any 
debris using a needle. The gasket was then replaced in the diamond anvil cell, lining 
the indent hole up with the diamond face to form a sample chamber. A few rubies 
were then added to the chamber using a needle. On top of this the sample was added, 
compressing the powder using the top diamond and adding more sample until the 
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increased incrementally by tightening the screws one by one in a clockwise fashion. 
Increasing the pressure applied to the sample in this clockwise gradual fashion 
allows a more even distribution of pressure. This screw method allows the pressure 
to be maintained for prolonged periods. For visual representation of this see Figure 
12. 
 
2.4.2 Raman Pressure Studies 
The Raman spectrometer laser was aligned using the alignment tool and 
experimental window on Omnic, by centring the crosshairs on the pin hole generated 
by the alignment tool. The instrument was then calibrated using Omnic. The ruby 
pressure was calibrated by measuring the fluorescence of a number of rubies at 
ambient pressure on the pressure setting on Omnic. The peak positions of the 
fluorescence peaks were fitted using a Voigt function. 5 readings were taken and the 
average was then used to give a mean inital pressure for measurement of the pressure 
of the diamond anvil cell. To measure the pressure exerted on the diamond anvil cell 
at each pressure increase, the ruby fluorescence of one of the rubies was taken as 
above and from this the pressure was calculated using the formula  ൭൬ቀ ೃೠ್೤ೌ೟ುೃೠ್೤಺೙೔೟೔ೌ೗ቁళǤలలఱ൰ିଵ൱ൈଵଽ଴ସ଻Ǥ଺଺ସ . To ensure consistency in the pressure measurement the 
pressures were recorded using the same ruby every time. The diamond anvil cell was 
moved to an area of the sample where no rubies were present to avoid the 
fluorescence, and the Raman spectrum of the sample was taken. The sample was 
collected over 10-20s, employing a lower time limit of 10-15s when a flat top was 
observed for the sample peaks. This was carried out until the pressure reached 
approximately 8 GPa, as this is reaching the higher pressures seen previously in 
molecular studies and possibly the upper pressure limit of the cell. The pressure was 
then gradually released to allow analysis of the Raman spectra on reduction of 
pressure back to ambient and also to gradually allow the sample to undergo any 
reverse phase changes. The resultant samples could then be extracted from the gasket 
sample chamber and photographed using a Reichert Polyvar-Met Microscope 
analysed by infrared spectroscopy. 
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2.4.3 Infrared Spectroscopy 
The pressurised sample was removed from the gasket using a needle and added to the 
surface of an infrared spectrometer. Infrared spectroscopy was carried out on the 
sample, taking a background reading to ensure only the sample was measured. The 
pressurised sample was compared to the ball milled sample, the drug alone and the 
polymer alone to allow analysis of the effect of pressure on structure of the mixture.  
 
2.4.4 Drug Release Studies 
The pressurised samples were extracted from the gasket chamber using a needle and 
weighed, averaging at 30mg per sample. Using eppendorfs with built in filters, in 
vitro dissolution was carried out on a number of pressurised samples in 1ml 
simulated intestinal fluid without enzymes, adjusted to pH 6.8 and 1ml simulated 
gastric fluid without enzymes, adjusted to pH 1.2 at 37ºC±0.5. Both solutions were 
prepared as detailed in the British Pharmacopoeia (British Pharmacopeia 
Commission Secretariat of the Medicines and Healthcare Products Regulatory 
Agency, 2014) minus the addition of pancreatic enzymes or pepsin respectively as 
these reduced the shelf life of the media. The samples were originally tested in pH7.4 
phosphate buffered saline (PBS) however the stimulated fluids were favoured latterly 
as it was more comparable to oral drug delivery in vivo. The sample was placed 
within the filtered chamber and allowed to dissolve in the media. ȝOVamples were 
taken from the dissolution chamber and replaced with fresh media at 15 minutes, 30 
minutes and at 1 hour time intervals after the 1 hour mark for a further 8 hours, and 
then at 24 hours to measure drug release over time. 3 replicates were carried out in 
simulated intestinal and simulated gastric fluids each. For the PBS samples this was 
analysed using a nanoUV spectrometer however due to issues with the machine, 
HPLC was used latterly and found to be much more effective. Samples were 
analysed by HPLC using a UV detector at 246nm. A C-18 silica column was 
employed and the mobile phase utilised was a 60:40 water:acetonitrile (v/v) solution 
at a flow rate of 1ml/min as observed in another study (Foroutan and Watson, 
1999).This particular method was selected as it gave a readable area under the curve 
even at the low drug concentrations present initially. The validation could not be 
carried out by the author personally due to time restrictions and lack of availability of 
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HPLC machines. However the method was validated and used on a daily basis by 
other students in the department. Using the equation generated from a hydrocortisone 
calibration standard curve, the concentration of drug present was calculated from the 
area under the curve (equation 1 in table 1 taken from Figure 13). The calibration 
curve was generated using standard solutions of ȝJPO ȝJPO ȝJPO DQG
1mg/ml hydrocortisone in acetonitrile. Acetonitrile was used as dissolution of 
hydrocortisone alone was not full enough in simulated fluids due to its highly 
aqueous nature. To account for the removal of drug from the overall solution on 
replacement of fresh media, equation 2 in table 1 was used to give the overall 
percentage drug release.  
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Figure 13: HPLC calibration curve of hydrocortisone taken from the area under 
the curve values of 1ʅg/ml, 10ʅg/ml, 100ʅg/ml and 1mg/ml samples, where 
y=4.095x-0.6985 and R2=1 
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Table 1: Equations used to calculate percentage drug release 
 
Method Equation 
Mass of drug released from DAC 
samples at each time point 
 
(1)  
Given the equation of the calibration 
curve is y=0.4095x-0.6985 
Where: 
y = area under the curve (AUC)  
(mg.h.L-1) 
x= concentration of drug present in 
solution (ʅg/ml) 
 
Concentration of drug released (ʅg/ml) = 
(AUC+0.6985)/0.4095 
Percentage drug release from DAC 
samples at each time point accounting for 
100ʅl extracted due to total possible 
FRQFHQWUDWLRQEHLQJRQO\ȝJPO 
(2) 
% drug release = ((A+100ʅl)/(B/C))x100 
 
where 
A= concentration of solution (ʅg/ml) 
B= total drug initially present in delivery 
system (ʅg) 
C= total volume of solution (1ml) 
Mass of drug released from large volume 
press samples at each time point where a 
full 1ml sample could be extracted each 
time due to the greater concentration of 
drug present 
 
 
 
 
(3) 
Given the equation of the calibration 
curve is y=0.4095x-0.6985 
Where: 
y = area under the curve (AUC)  
(mg.h.L-1) 
x= concentration of drug present in 
solution (ʅg/ml) 
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Due to the cumulative nature of this 
method from the 30 minute reading 
(second time point) onwards the previous 
total sample concentration present (P) 
was added to the concentration measured 
at the current time point 
 
 
Initial 15 minute sample: 
Concentration of drug released (ʅg/ml) = 
(AUC+0.6985)/0.4095 
 
30 minutes onwards: 
Concentration of drug released (ʅg/ml) = 
((AUC+0.6985)/0.4095)+P 
 
Where P = previous total sample 
concentration present 
 
For example 
At 15 minutes:  
Concentration of drug released = 
((1.5563+0.6985)/0.4095) 
=5.51ʅg/ml (to 2 d.p.) 
 
At 30 minutes: 
Concentration of drug released = 
((0.6994+0.6985)/0.4095)+ 5.51ʅg/ml 
 ȝJPOWRGS 
 
At 1 hour: 
 
Concentration of drug released = 
((7.0118+0.6985)/0.4095)+ 8.92ʅg/ml 
 ȝJPOWRGS 
 
Percentage drug release from large 
volume press samples  
(4) % drug release = (A/B)x100 
 
Where  
A= concentration of drug released in 
solution 
B= total drug present in delivery system 
initially 
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2.4.5 Statistical analysis 
The maximum release achieved from the sample in simulated gastric and intestinal 
fluids was compared by unpaired t-tests. In addition any degradation was analysed by 
unpaired t-tests comparing pure hydrocortisone present with hydrocortisone plus any 
derivatives present. A P-value of less than 0.05 was deemed to be statistically 
significant. 
 
2.4.6 Differential Scanning Calorimetry (DSC) 
Standard DSC pans were filled with 2-5mg of sample, taking care to avoid 
contamination from the researcher or the surfaces worked on. The pan lids were 
punched with a central hole using a needle to prevent rupture at over 80ºC. The pans 
were then heated over a range of 40-290ºC, using the differential scanning 
calorimeter detailed in the apparatus section, to allow melting of both PEG (which, 
from the manufacturer¶VGDWD was believed to have a melting point between 58 and 
61ºC) and hydrocortisone (which was believed to have a melting point between 
211and 214ºC). The resultant curves were then analysed and visual observations on 
reopening the pans were recorded. Some of the samples were also analysed by 
infrared spectroscopy to analyse the change in structure of the drug and polymer 
blend on heating, compared to the ballmilled and pressurised samples. 
 
2.4.7 Thermogravimetric Analysis (TGA) 
Standard 150ʅl TGA ceramic covered crucibles were filled with 10-20mg of sample, 
taking care to avoid contamination or filling the crucibles by more than 75%. The 
samples were then heated over ranges of 55-500°C for the blends and pure PEG, and 
150-550° C for pure hydrocortisone, using the thermogravimetric analyzer detailed 
in the apparatus section. This allowed analysis of the interactions between PEG and 
hydrocortisone. The resultant curves were then analysed. 
 
2.4.8 Temperature vs. Pressure Studies 
The ability of pressure to reduce the temperature required melt polyethylene glycol 
was hypothesised from the fact a phase change occurs at 25ºC (room temperature) at 
5GPa, as demonstrated by the visual transformation of the white powder into a 
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transparent liquid and changes in the Raman spectra, whereas the above differential 
scanning calorimetry study identified a higher melting point at ambient pressure 
(0GPa), with troughs occurring at between 55 and 65°C on the resultant spectra. The 
diamond anvil cell was loaded with polyethylene glycol. The sample was pressurised 
and then placed in an oven for 2 hours, starting at 30ºC and increasing the 
temperature by 5 degrees each time. At each increase in temperature, the effect was 
measured visually and via Raman spectroscopy. This was carried out at 0.8GPa, 
1GPa, 2GPa, 3GPa and 4 GPa, to measure the relationship between pressure and 
temperature. 
 
2.4.9 Pressure Scale Up 
A PTFE cell (see Figure 14) was loaded with 50:50 PEG:hydrocortisone mixed with 
a pressure transmitting medium (water initially and then petroleum ether latterly). 
The cell was sealed at both ends using plastic caps sealed with PTFE tape. The cell 
was then placed in a beryllium copper alloy (BERYL CO-25) outer cell and pushed 
in to place using a tungsten carbide pusher, sealing it with copper rings. A piston was 
added and vacuum grease applied to lubricate it, before adding a spacer. A retaining 
nut was then added to the end and a carbon tungsten rod was placed on top of the 
inner cell. For a visual representation of this cell see Figure 14. Pressure was then 
exerted on the cell using a hydraulic ram and locked in place by tightening the 
retaining nut. This pressurising step was repeated until a pressure of 0.8 GPa was 
achieveG7KHFDUERQ WXQJVWHQ URG ZDV WKHQ UHPRYHGDQG WKHFHOOZDVSODFHG LQ D
ࡈ&RYHQRYHUQLJKW WRDOORZWKH3(*WRIXOO\PHOW7KHSUHVVXUHZDVWKHQEDFNHG
off by reversing the previous steps. The inner cell was then pushed out of the bottom 
of the outer cell and the sample extracted and allowed to dry. For the sample using 
water as a pressure transmitting medium, the addition of an ultrafiltration step was 
required as it generated a very wet sample. Drug release studies were carried out 
using eppendorfs with filters, but unlike the previous drug release studies the whole 
1ml was removed and replaced each time, instead of just 100µl, as the greater mass 
of drug added allowed this to occur and it was hoped this would reduce degradation 
of the drug occurring in the stagnant dissolution media. Drug release was calculated 
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using equations 3 and 4 in table 1, and statistical analysis was carried out as in 
section 2.4.5. 
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Figure 14: A large volume pressure cell set 
up consisting of an inner cell (left) and an 
outer cell (right).  
PTFE cell PTFE caps 
Copper rings 
Carbon 
tungsten rod 
Retaining nut 
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Beryllium 
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Chapter 3: Results 
 
3.1 PEG 
 
The effect of pressure from a visual perspective can be seen in Figure 15. The white 
crystalline powder is observed to change gradually change into a clear liquid as the 
pressure is increased. The white powder was observed to be fully melted around 
5GPa, as marked by a shiny texture through the microscope. On removal of the 
pressure and reopening of the diamond anvil cell a transparent solid mass is formed 
as seen in the latter pane of Figure 15. The ragged edges of the samples illustrate the 
flow that has occurred.  
 
3.1.1 Raman 
In Figure 16 initially at ambient pressure a distinct sizable ridged peak can be seen at 
approximately 2900 cm-1 and a smaller distinct peak with a step like conformation at 
approximately 844 cm-1. The former falls in the CH region of the spectra and thus 
corresponds to the carbons attached to hydrogen atoms found in the main chain of 
PEG4000.  The latter falls in the C-O-C region of the spectra and thus is the distinct 
C-O-C bond pattern found in PEG 4000. There are other peaks present in the 
spectrum but they do not show distinct changes. On application of pressure the ridges 
of the CH peak are lost and the peak becomes smooth in a gradual manner, becoming 
completely smooth by 5GPa, signifying the stretching of the CH groups are tending 
towards a similar energy. The axis breaks are due to the diamond peak being 
removed from the spectra (~1300 cm-1). In Figure 17 shift to higher wavenumber in 
Figure 15: In the left hand pane the initial unpressurised powder can be observed and 
in the right pane one of the samples generated on taking the pressure exerted up to 
5GPa and then returned to ambient. 
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this region caused by increasing pressure can be observed. There appears to be a 
linear relationship between pressure and Raman shift, with the increase in Raman 
shift being directly proportional to the increase in pressure.  
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 Figure 16: Raman spectra of PEG4000 illustrating the changes occurring on 
increasing pressure 
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Figure 17: Raman Shift of the CH 2900 cm-1 region of PEG4000, occurring with 
increasing pressure where n=5 SE± 0, 3.31, 2.41, 3.31, 2.41, 3.21, 3.40 and 3.36 
cm-1 respectively. The horizontal error bars represent the 0.05GPa margin of error 
of each pressure.  
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Figure 18 is a zoom in to the C-O-C region. It is observed to consist of a step like 
peak and as the pressure is increased the lower portion of the peak is seen to 
gradually diminish, completely disappearing by 5GPa. The Raman shift of the main 
C-O-C peak is illustrated in Figure 19. The shift to a higher wavenumber and 
increase in Raman shift is again directly proportional to the increase in pressure, as 
shown by the fairly linear treadline.  
 Figure 18: Raman Spectra of the C-O-C region of PEG4000 and the effect of 
increasing pressure  
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Figure 19: Raman Shift of the C-O-C 844 cm-1 region of PEG4000, occurring with 
increasing pressure where n=5 SE± 0, 0.459295, 0.602906, 1.393178, 0.83855 and 
2.029418 cm-1 respectively. The horizontal error bars represent the 0.05GPa margin 
of error of each pressure.  
Figure 20: Raman Spectra of the C-O-C region of PEG4000 on removal of 
pressure.  
In Figures 20 and 21, the effect of pressure removal is shown. In Figure 20 the 
smaller step-like feature of the C-O-C region returns on removal of pressure 
reforms as PEG becomes a solid once more. Likewise in Figure 21 the ridges of the 
CH region are observed to return, as shown by the fact that once the pressure is 
removed the spectra in B) returns to more like A) as shown in C). 
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Figure 21: Raman spectra illustrating A) PEG4000 in ambient before pressure, B) 
PEG4000 at 5.6GPa and C) PEG4000 after the pressure is removed again. 
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 3.1.2 Infrared Spectroscopy 
In Figure 22, the effect of pressure on the functional groups of PEG4000 can be 
observed.  The 1096 cm-1 region corresponds to the C-O-C region. In the ambient 
sample spectra this peak is approximately 2.4-fold higher than the surrounding peaks, 
with the next highest peak at the CH group at 841 cm-1 reaching 0.276162AU 
compared to 0.666641AU. Whereas, after pressure, although all the peaks decrease 
in height, this peak is approximately 1.7-fold higher than the surrounding peaks at 
0.01818AU compared with 0.01063AU for the next highest peak. The decrease in 
proportion of this peak relative to the surrounding peaks may suggest there is less of 
a prominence of this functional group in the structure which may suggest there is a 
change in structure. Changes in this particular region support the changes in C-O-C 
Raman peaks.  
Figure 22: Infrared spectra of PEG4000 A) before and B) after pressure is exerted 
on the powdered sample.  
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3.1.3 Differential Scanning Calorimetry 
On application of heat, PEG4000 was found to melt over the range of 59.23 to 
64.37°C, reaching its peak at 62.48°C (Figure 23). Again the white powder turned 
into a transparent liquid on reaching the melting range and then became a solid 
transparent mass. Table 2 illustrates all three replicates the author took of PEG4000 
and the mean results with the standard error.  
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Differential scanning calorimetry spectrum of PEG4000  
Temperature (°C) 
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Sample Onset Temperature 
(°C) 
Extrapolated Peak 
Temperature (°C) 
Endset Temperature 
(°C) 
1 59.23 62.48 64.37 
2 57.44 60.46 61.50 
3 59.35 62.25 64.97 
Average 58.67 61.73 63.61 
S.E. 0.617639 0.638462 1.070768 
 
 
 
 
Table 2: Differential scanning calorimetry from 3 replicates of PEG4000, giving 
the mean onset, extrapolated peak and endset temperatures.  
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Figure 24: Infrared Spectra of PEG4000 illustrating the effect of DSC treatment 
on the sample exemplified by A) PEG4000 under ambient conditions and B) 
After DSC treatment. 
In Figure 24, the effect of DSC exposure can be observed. Similar to the infrared 
spectra of the pressurised sample, the C-O-C peak at 1096 cm-1  is observed to 
drop from 0.66664AU, which is 2.4-fold higher than the CH 841 cm-1 peak at 
0.27616AU, to 0.2176AU, which is 2-fold higher at than the next highest peak at 
0.10745AU. There is also an overall decrease in peaks but again the C-O-C peak 
is the most marked decrease. 
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3.1.4 Thermogravimetric Analysis 
On application of high temperatures, PEG4000 was found to almost entirely degrade 
over a temperature range of approximately 335-450°C (Figure 25). This temperature 
at which degradation occurs is significantly distinct from the melting range at 
approximately 57-65°C given by the differential scanning calorimetry results (Figure 
23 and Table 2) but this shows that the polymer is stable well beyond its melting 
temperature. Table 3 gives all three replicates of PEG4000 and a mean and standard 
error for the temperature ranges and percentage degradation of the thermogravimetric 
analysis samples. The white powder became blackened and reduced in mass on 
degradation due to the carbon burning, giving off a strong smell. 
 
 
 
 
 
 
 
Figure 25: Thermogravimetric analysis of PEG4000   
Temperature (°C) 
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Sample Approximate 
Temperature 
Range (°C) 
Percentage 
degradation (%) 
 
1 335-450 96.2534 
2 340-440 96.665 
3 330-445 96.6668 
Average 335-445 96.5284 
S.E. 2.886751 0.137501 
 
 
Table 3: Thermogravimetric analysis of 3 replicates of PEG4000 which gives the 
mean peak degradation.  
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3.1.5 Temperature Studies 
To explore the phenomenon of the polymer flowing under pressure the melting 
temperature of PEG4000 with respect to pressure was probed. Figure 26 illustrates 
the relationship between temperature and pressure on PEG4000 and shows a linear 
relationship with temperature being inversely proportional to pressure. The graph 
provides the basic physicochemical description of PEG4000 with temperature and 
pressure which would be required for the subsequent studies of drug loading using 
the large volume press. 
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Figure 26: The mean relationship between temperature and pressure in the melting of 
PEG, where n=3, the vertical error bars from left to right represent SE±0.638462°C, 
0.666667°C, 0°C, 1°C, 0.666667°C, 0.333333°C and 0°C respectively. The 
horizontal error bars represent the 0.05 GPa margin of error generated by the Raman 
Spectrometer.  
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3.2 Hydrocortisone 
 
3.2.1 Raman 
In Figure 27 a visual representation of the effect of pressure on the hydrocortisone 
which originates as a white crystalline powder can be observed. Like PEG it loses its 
colour but unlike PEG it does not fully melt, merely becoming compressed.  
In Figure 28 initially at ambient pressure a distinct ridge topped peak can be seen at 
approximately 2890 cm-1 and a distinct double peaked structure can be seen with 
peaks at approximately 1611 cm-1 and 1644 cm-1. Like PEG4000, the former falls in 
the CH region of the spectra and thus could correspond to the aromatic rings found in 
the structure of hydrocortisone.  The 1611 cm-1 and 1644 cm-1 peaks fall in the C=C 
region, corresponding to the alkene regions of the steroid backbone. Two of the 
polymorphs of hydrocortisone require two molecules to describe the whole structure 
so the peaks at 1611 and 1644 cm-1 represent the alkene group on each of these 
molecules. There are other peaks present in the spectrum, but they do not show 
distinct changes. On application of pressure the ridges of the CH peak are lost and 
the peak becomes smooth in a gradual manner, becoming completely smooth by 
5GPa. Again the axis breaks are due to the diamond peak being removed from the 
spectra (~1300 cm-1). The peak observed just to the right of the CH peak in some of 
the spectra is due to a slight influence of the diamond, largely due to the fact that the 
fluorescence of hydrocortisone makes it slightly more difficult to focus on than PEG 
alone. In Figure 29, the shift to a higher wavenumber in this region caused by 
increasing pressure can be observed. There appears to be a fairly linear relationship 
between pressure and Raman shift, with the shift to a higher wavenumber and thus 
Figure 27: Hydrocortisone after pressurising. It should be noted the dark circles are 
the rubies used to test the pressure. 
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increase in Raman shift being directly proportional to the increase in pressure. In 
Figure 28, with increasing pressure, the alkene peaks are observed to become less 
defined and eventually merge into a single peak by approximately 4 GPa. Figure 30 
illustrates the merging of these two peaks. The merged peak is latterly observed to 
shift to a higher wavelength suggesting after the merging, the increase in Raman shift 
seen previously with the CH peak in Figure 29, is replicated in the merged peak. 
Similarly to PEG4000, on removal of pressure the peaks return to their ambient state 
as exemplified by Figure 31. 
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Figure 28: Raman spectra of hydrocortisone illustrating the changes occurring on 
increasing pressure 
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  Figure 29: Raman shift of the 2888cm-1 CH region of hydrocortisone, in which 
n=5 and SE±0, 7.65, 6.43, 7.81, 9.41 and 9.96cm-1 respectively. The horizontal 
error bars have the value of 0.05GPa determined by the Raman spectrometer.. 
Figure 30: The Raman shift of the 1611cm-1 and the 1644cm-1 C=C peaks in which 
n=5 and SE±0.311429, 0.834003, 3.352016, 0.269756, 0.240704 and 0.72436cm-1 
for the 1611cm-1 peak, and 0.198515, 1.765453, 0.3172, 0.269756, 0.240704 and 
0.72436cm-1 for the 1644cm-1 peak respectively. The horizontal error bars have the 
value of 0.05GPa determined by the Raman spectrometer. 
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Figure 31: Raman spectra of A) hydrocortisone initially, B) at 5GPa and 
C) after pressure removal, illustrating return of the original peaks. 
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3.2.2 Infrared Spectroscopy 
In Figure 32, the effect of pressure on the functional groups of hydrocortisone as 
illustrated by infrared spectroscopy can be observed. All the peaks are diminished by 
pressure by around 9-fold but the greatest change is in the C=C 1642 cm-1 as the 
difference in this peak from the next highest peak at 1046 cm-1, representing C-O, is 
observed to decrease from 1.93-fold at ambient (A) to 1.28-fold after pressure (B), 
making the change in this particular peak nearly 10-fold, falling from 0.04401 to 
0.00466AU, with the next highest peak falling from 0.02284 to 0.00363AU. The 
latter spectrum (B) is not a particularly good representation but this was consistent 
with all the samples taken from the diamond anvil cell. This may be, in part, due to 
the necessarily small samples that we have to use for the pressure experiment. 
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Figure 32: Infrared spectra of hydrocortisone illustrating the changes occurring B) 
after pressure is applied and removed by comparison to the A) original ambient 
sample. 
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3.2.3 Differential Scanning Calorimetry 
On application of heat, Hydrocortisone was found to melt over the range of 223.61 to 
228.06°C, reaching its peak at 226.87°C (Figure 33). Table 4 illustrates all three 
replicates the author took of hydrocortisone and the mean results with the standard 
error. Unlike PEG and the pressurised sample, white powder turned into a bright 
marigold yellow liquid on reaching the melting range and then became a solid shiny 
yellow mass which is shown in Figure 43. This colour change was suggested to be 
FDXVHG E\ IRUPDWLRQ RI WKH GHJUDGDWLRQ SURGXFW ȕɲ-dihydroxy-3,20-dione-4-
pregnene-21-al (Connor, 1974). This colour change is not observed on pressurising 
the sample suggesting this phase change is not occurring on pressurising.  
 
 
 
 
 
 
Figure 33: Differential Scanning Calorimetry of hydrocortisone 
Temperature (°C) 
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Table 4: Differential scanning calorimetry of 3 replicates of hydrocortisone, with the 
mean onset, extrapolated peak and endset temperatures. 
 
Sample Onset Temperature 
(°C) 
Extrapolated Peak 
Temperature (°C) 
Endset Temperature 
(°C) 
1 223.50 227.13 228.46 
2 223.61 226.97 228.06 
3 223.35 226.68 227.93 
Average 223.49 226.93 228.15 
S.E. 0.075351 0.131698 0.159478 
 
 
In Figure 34, the effect of DSC exposure on the infrared peaks can be observed. 
Unlike the pressurised sample, the peaks of the DSC sample (B) actually increase in 
size relative to the ambient sample (A). The greatest increases are found to be in the 
CH alkane region at around 2933 cm-1, with a 2.75-fold increase from 0.00689 to 
0.01892AU, the C=O region at approximately 1706 cm-1, with a 2.23-fold increase 
from 0.01353 to 0.03011AU, the CO region at approximately 1046 cm-1, with a 1.96-
fold increase from 0.02284 to 0.04488AU, and the C=C region at around 1642 cm-1, 
with a 1.89-fold increase from 0.04401 to 0.08322AU. The OH region at 3428 cm-1, 
does not exhibit as large an increase with only a 1.24-fold increase from 0.00964 to 
0.01196AU.  
 
The increase in peak size suggests there is actually a considerable change happening 
in the molecule on melting which is not occurring on pressurising. This may suggest 
the formation of an initial degradation product. This is particularly suggested by the 
fact that the C=O peak increases from a 1.4-fold difference from the smaller OH 
peak to a 2.52-fold difference. Which may be attributed to the conversion of the 
DOFRKRO JURXS WR DQ DOGHK\GH JURXS LQ WKH IRUPDWLRQ RI ȕɲ-dihydroxy-3,20-
dione-4-pregnene-21-al (Connor, 1974). The absence of these changes in the 
pressurised sample spectra suggest that unlike under high temperature, pressure does 
not induce degradation.  
59 
 
Figure 34: Infrared spectra of hydrocortisone illustrating the effect of DSC 
treatment on the functional groups, as illustrated by a comparison of the 
spectra A) before and B) after DSC treatment. 
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3.2.4 Thermogravimetric Analysis 
On application of high temperatures, hydrocortisone was found to degrade by around 
8% less than PEG4000 over a temperature range of approximately 240-520°C 
(Figure 35). This temperature at which degradation occurs is distinct from, although 
still quite close to, the melting range at approximately 223-228.5°C given by the 
differential scanning calorimetry results (Figure 33 and Table 4). There is an 
interesting almost double step pattern seen in the degradation.  This could suggest the 
degradation is occurring LQVWHSVSHUKDSVWKLVILUVWVWHSLVȕɲ-dihydroxy-3,20-
dione-4-pregnene-21-al formation at around 300ºC (Connor, 1974). Table 5 gives all 
three replicates of hydrocortisone and a mean and standard error for the temperature 
ranges and percentage degradation of the thermogravimetric analysis samples. The 
white powder became blackened and reduced in mass on degradation due to the 
carbon burning, giving off a strong smell in decomposition. 
 
 
 
 
 
Figure 35: Thermogravimetric analysis of hydrocortisone illustrating the 
degradation of the drug under high temperatures. 
Temperature (°C) 
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Table 5: Thermogravimetric analysis of 3 hydrocortisone replicates, giving the mean 
percentage degradation.   
 
Sample Approximate 
Temperature 
Range (°C) 
Percentage 
degradation (%) 
1 240-515 88.3414 
2 235-520 88.7822 
3 240-500 88.6812 
Average 238.33-511.67 88.6016 
S.E. 6.009252 0.133327 
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3.3 PEG and Hydrocortisone 
 
3.3.1 Raman  
In Figure 36 a visual representation of a PEG:Hydrocortisone blend after pressure 
can be observed, illustrating that again PEG melts and becomes translucent and the 
hydrocortisone particles can be faintly observed.  
 
Initially the author looked at 90:10 and 80:20 PEG:Hydrocortisone blends, however 
as the blend taken forward was the 50:50 blend the results of the former can be 
observed in the appendices and seen to follow a very similar pattern with the only 
major difference being the size of the hydrocortisone peaks. In Figure 37, at ambient 
pressure a distinct sizable ridged peak can be seen at approximately 2900 cm-1 which 
is a combination of PEG4000 and hydrocortisone. The distinct double peaked 
structure of hydrocortisone at 1611 cm-1 and 1644 cm-1, corresponding to the alkene 
peaks, can also be observed at a lesser intensity than pure hydrocortisone. The 
smaller distinct peak with a step like conformation at approximately 844 cm-1 C-O-C 
of PEG can also be observed. The CH region of the spectra corresponds to a 
combination of the carbons attached to hydrogen atoms found in the main chain of 
PEG4000 and the aromatic rings of hydrocortisone.  On application of pressure the 
ridges of the CH peak are lost and the peak becomes smooth in a gradual manner, 
becoming completely smooth by 5GPa. The alkene peaks again merge by 4GPa. 
Figure 38 is a zoom in to the C-O-C region. It is observed to consist of a step like 
peak and as the pressure is increased the lower portion of the peak is seen to 
gradually diminish, completely disappearing by 5GPa. In Figure 39 the smaller step-
like feature of the C-O-C region is observed to return on removal of pressure return 
Figure 36: PEG:Hydrocortisone after pressure 
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as the PEG resolidifies and the distinct double peak of hydrocortisone are also 
observed to return.   
Figure 37: Raman spectra of the 50:50 PEG:hydrocortisone sample, illustrating 
the effect of increasing pressure on the peaks.  
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Figure 38: Raman spectra of the 844cm-1 C-O-C of the 50:50 PEG:hydrocortisone 
sample, illustrating the effect of increasing pressure on the peaks. 
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Figure 39: Raman Spectra illustrating the effect of pressure removal by comparison of 
the 50:50 PEG:hydrocortisone sample (A) at ambient pressure, (B)  at 5GPa and (C) 
after pressure removal. 
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3.3.2 Infrared Spectroscopy 
Again the data for the 90:10 and 80:20 PEG:Hydrocortisone blends can be found in 
the appendices and the only difference to the 50:50 blend is the fact that the 
hydrocortisone peaks are less prominent. In Figure 40 all the peaks are diminished by 
pressure but as with pure PEG the greatest decrease is seen in the 1096 cm-1 region 
corresponding to the C-O-C region. In the ambient sample spectra (A) this peak, at 
0.64335AU is 3.24-fold higher than the next highest peak at 842 cm-1, with an 
absorbance of 0.19883AU. Whereas, after pressure (B), although all the peaks 
decrease in height, this peak, at 0.09451AU, is only 2.58-fold higher than the 842 
cm-1 peak, at an absorbance of 0.03661AU. The change in this particular region 
supports the changes in C-O-C Raman peaks. Hydrocortisone peaks can be seen at 
the OH region at 3429 cm-1, the C=O region at 1706 cm-1 and the aromatic C=C 
region at 1630 cm-1, and their size is directly proportional to the percentage of 
hydrocortisone present at ambient.  The hydrocortisone peaks are seen to fall after 
pressure with the OH region falling from 0.02412AU to an absorbance less than zero, 
the C=O region falling from 0.03158 to 0.00607AU and the C=C region falling from 
0.07021 to 0.00531AU.  This is undoubtedly due to experimental error during the 
collection of the background and subsequent sample readings. 
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Figure 40: Infrared spectra of the 50:50 PEG:hydrocortisone sample, 
illustrating the effect of pressure on the functional groups. 
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3.3.3 Differential Scanning Calorimetry 
Again the data for the 90:10 and 80:20 PEG:hydrocortisone blends is shown in the 
appendices. In Figure 41, the 50:50 blend showed a PEG melting range of 57.72 to 
63.46°C, reaching its peak at 61.01°C, and a hydrocortisone melting range of 186.91 
to 208°C, reaching its peak at 203.04°C.  Table 8 illustrates all three replicates the 
author took of hydrocortisone and the mean results with the standard error. In Figure 
42, the effect of DSC exposure on the infrared spectrum can be observed. As the 
PEG4000 peaks decrease as before, the hydrocortisone CH influence becomes more 
prominent. The 3.24-fold difference in the 1096 cm-1 PEG peak, at 0.64346AU, 
relative to the next highest peak, at 0.19883AU, at ambient drops to a 2.77-fold 
difference, comparing the 841 cm-1 peak at 0.16436AU with the 1096 cm-1 peak at 
0.45464AU, after pressure has been applied and removed confirming the same 
reaction still occurs in the presence of hydrocortisone. Figure 43 shows the DSC 
pans which have been reopened after heating, hydrocortisone and PEG are both 
observed to have undergone colour changes with the former undergoing a white to 
yellow colour change and the latter undergoing a white to colourless change, both of 
which are believed to have occurred on melting. 
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 PEG 
 
Hydrocortisone 
Sample Onset 
(°C) 
Extrapolated 
Peak (°C) 
Endset  
(°C) 
Onset 
(°C) 
Extrapolated 
Peak (°C) 
Endset  
(°C) 
1 57.88 60.76 64.10 187.24 204.56 209.04 
2 58.18 61.53 63.50 187.85 204.14 208.50 
3 57.72 61.01 63.46 186.91 203.04 208.00 
Average 57.93 61.1 191.06 187.33 203.91 208.51 
S.E. 0.13483 0.22679 0.20699 0.27534 0.45319 0.30030 
Figure 41: Differential scanning calorimetry of the 50:50 PEG:hydrocortisone 
sample, showing the melting points for PEG and hydrocortisone. 
Table 8: Differential scanning calorimetry of 3 replicates of 50:50 
PEG:hydrocortisone, with the mean onset, extrapolated peak and endset 
temperatures. 
Temperature (°C) 
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Figure 42: Infrared spectra of the 50:50 PEG:hydrocortisone sample, illustrating 
the effect of DSC treatment on the functional groups. 
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3.3.4 Thermogravimetric Analysis 
Again the data for the 90:10 and 80:20 PEG:hydrocortisone samples is shown in the 
appendices. On application of high temperatures, the 50:50 PEG:hydrocortisone 
blend was found to almost entirely degrade over a temperature range of 
approximately 215-475°C (Figure 44). The percentage degradation is about around 
7% less and the temperature range starts about 120°C lower and 30°C higher than 
PEG alone. The step formation of hydrocortisone can also be faintly observed. This 
temperature at which degradation occurs is significantly distinct from the melting 
ranges at approximately 57-65°C for PEG and 160-210°C for hydrocortisone given 
by the differential scanning calorimetry results (Figure 24 and Table 2). Table 11 
gives all three replicates and a mean and standard error for the temperature ranges 
and percentage degradation of the thermogravimetric analysis samples. Again the 
white powder became blackened and reduced in mass on degradation due to the 
carbon burning, giving off a strong smell. 
 
 
 
 
 
Figure 43: DSC pans containing hydrocortisone (left) and PEG4000 (right) after 
exposure to over 210°C and 60°C respectively 
72 
 
 
 
 
 
 
 
 
Sample Approximate 
Temperature 
Range (°C) 
Percentage 
degradation (%) 
1 215-475 89.0733 
2 220-480 89.4071 
3 210-470 89.6723 
Average 215-475 89.38 
S.E. 2.886751  0.173294 
 
 
 
Figure 44: Thermogravimetric of the 50:50 PEG:hydrocortisone sample, showing 
the percentage degradation occurring. 
Table 11: Thermogravimetric analysis of 3 replicates of 50:50 
PEG:hydrocortisone, giving the mean percentage degradation. 
Temperature (°C) 
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3.3.5 Drug Release Studies 
50:50 Samples were selected to take forward in the current study due to them being 
the most comparable to previous formulations. Initially a drug release study was 
carried out in pH7.4 PBS analysing the drug release using UV spectrometry. For the 
PBS study there was only one replicate due to major issues with the nanoUV 
spectrometer in latter studies (absorbance was showing as negative figures in latter 
studies even on the standard solutions). This was attributed to the self cleaning 
function of the spectrometer occurring simultaneously to the absorbance reading 
causing the spectrometer to effectively read air instead of the sample. The samples 
were not suitable for use with a normal UV as the extracted samples were too small 
to be read in a cuvette. This was also not repeated as the simulated intestinal and 
gastric fluid media were more comparable to gastrointestinal fluids and thus with 
limited time were considered to be of more value to the study. However, the author 
chose to still include this as the curve in Figure 45 exhibited the same immediate 
release, sustained release, immediate release pattern as the later drug release studies 
(Figures 46, 51 and 52). Figure 45 shows both release over 6 hours and over the full 
24 hours. Initially there is a rapid increase in drug release from the diamond anvil 
cell samples over the first 30 minutes of the study, with 10.67% being released by 
this point. There is then a period of sustained release of 2 and a half hours, with 13% 
release by the end of this, before another rapid increase in drug release over the next 
2 hours, up to  77.49%. 115.58% has released by 24 hours. This is slightly over the 
total mass expected to be present. One of the limitations of the study is that the 
sample inserted into the diamond cell was necessarily small and so despite ensuring a 
well-mix sample using the ball mill we could not ensure a evenly distributed sample 
in the cell.  For this reason 5 sample disks generated by the diamond anvil cell were 
used in the drug release but there are still failings in this study. 
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Figure 45: Drug release from DAC samples in pH7.4 PBS using nanoUV 
analysis, where n=1 (due to issues with the nanoUV replicates could not be 
taken). The top pane (A) illustrates the first 6 hours and the bottom pane (B) 
illustrates the full 24 hours 
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Latterly the drug release from the 50:50 PEG4000:hydrocortisone diamond anvil cell 
samples was studied in simulated intestinal and gastric fluids. The analysis method 
was switched to HPLC which in fact gives more information about what happens to 
the drug. Figure 46 illustrates the drug release in simulated intestinal and gastric 
fluids. HPLC revealed that hydrocortisone was degrading in aqueous solutions, as 
once the drug release was analysed additional area under the curve peaks were found 
to be present close to the main drug peak. From the literature, these peaks were found 
to be hydrocortisone derivatives (Walters and Dunbar, 1982). As such Figure 46 
illustrates the drug release looking at the pure drug present alone and the drug release 
taking into account the derivatives which have formed in the stagnant drug release 
media. Similar to Figure 45, drug release was found to occur in a step-like manner.  
 
Looking at the drug and derivative samples first, initially an immediate release burst 
can be observed in both simulated intestinal and gastric fluids. In the former this 
takes the form of an average release of 55.89% over 30 minutes and in the latter this 
takes the form of 54.02% over 1 hour. This is then followed by a sustained release 
period of 5 and a half hours for the simulated intestinal fluid sample, by which point 
a total average release of 72.77% had occurred. For the simulated gastric fluid, the 
initial burst is again followed by a sustained release period, this time of 5 hours, by 
which a total average release of 62.25% had been achieved. For both the simulated 
intestinal and gastric fluid samples the sustained release period was followed by 
another immediate release burst over 2 hours to the 8 hour time point. By 8 hours, an 
average of 111.4% had been released in simulated intestinal fluid and an average of 
107.88% had been released in simulated gastric fluid. For both sets of samples, drug 
release was shown to have levelled off by a final 24 hour time point. Surprisingly 
this time point was at 97.87% and 89.57% in simulated intestinal and gastric fluids 
respectively. This may be attributed to greater degradation. As 8 hours was found to 
be the peak of the curve unpaired T-tests were carried out in OriginPro comparing 
the mean maximum release of the pure and derivative containing samples. The P-
value was found to be less than 0.05, at a value of 0.024, and thus the difference 
between the two maximums is significant. 
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Observing the pure drug samples, initially again an immediate release burst can be 
observed. However this only reached an average of 12.24% drug release at 30 
minutes in simulated intestinal fluid and 11.38% at 1 hour in simulated gastric fluid. 
Again there was a period of sustained release lasting 5 and a half hours in simulated 
intestinal fluid, during which the average drug release reached was 19.06%. This is 
then followed by another immediate release burst of 2 hours, reaching the 8 hour 
time point at 41.84%. Again this drops by the 24 hour time point, which may be due 
to increased degradation, reaching an average of 24.15% release. Likewise in the 
simulated gastric fluid there is a sustained release period starting after the initial burst 
of release, however, unlike in simulated intestinal fluid, this prevails until the 24 
hour time point at 28.54% release. Thus there is only 18.70% release by the 8 hour 
time point. It should be noted all of the samples have quite big error bars, even 
though they correspond to standard error rather than standard deviation, the largest of 
which are found with the samples consisting of both hydrocortisone and its 
derivatives. The standard error values are detailed in A3.1 of Appendix 3. Unpaired 
T-tests were once again carried out in OriginPro comparing the mean maximum 
release of the pure and derivative containing samples. The P-value was found to be 
less than 0.05, at a value of 0.00439, and thus the difference between the two 
maximums is significant. In addition to this unpaired T-tests were carried out 
comparing the samples in different media. Both the pure and derivative containing 
samples were found to have maximum release values not significantly different from 
each other in different media as both had P-values over 0.05 at 0.38628 and 0.80281 
for the pure and derivative samples respectively.  
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Figure 46: Drug release from 50:50 PEG:hydrocortisone DAC samples in pH6.8 
simulated intestinal fluids (SIF) and simulated gastric fluids (SGF). The pure 
samples and those with the degradation derivatives are both shown. For each 
sample n=3 S.E.± values detailed in Appendix 3. For the difference between pure 
and derivative containing samples P<0.05, but for comparison of the samples 
different media P>0.05. 
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3.4 High Pressure Scale Up 
 
3.4.1 Raman 
On scale up, once again the author looked at a 50:50 PEG:hydrocortisone blend. In 
Figure 47, the sample generated using water as a pressure transmitting medium is 
compared with hydrocortisone alone, PEG alone and also an ambient sample.  The 
2900 cm-1 peak is thought to be a combination of PEG4000 and hydrocortisone due 
to the peak being very like the hydrocortisone CH peak but has the height of the PEG 
one and also an additional ridge at the top of the peak. However the rest of the 
Raman spectra appears to mirror the hydrocortisone spectrum with a very prominent 
double peaked structure of at 1611 cm-1 and 1644 cm-1, corresponding to the alkene 
groups, and lesser peaks at lower wavenumbers which also seem to be more like 
those of hydrocortisone than PEG.  
 
In Figure 48, the 50:50 PEG:hydrocortisone sample generated using petroleum ether 
as a pressure transmitting medium is compared with hydrocortisone alone, PEG 
alone and an ambient 50:50 PEG:hydrocortisone sample. The physical 
characterisation of this spectrum is much more comparable to the diamond anvil cell 
samples (Figure 37) as there is a much more even distribution of PEG and 
hydrocortisone. 
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Figure 47: Raman spectra comparing the functional groups of the D) 50:50 
PEG:hydrocortisone large volume sample made using water as a pressure 
transmitting medium with that of the A) unpressurised sample, B) PEG4000 and 
C) hydrocortisone. 
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Figure 48: Raman spectra comparing the functional groups of the D) 50:50 
PEG:hydrocortisone large volume sample made using petroleum ether as a 
pressure transmitting medium with that of the A) unpressurised sample, B) 
PEG4000 and C) hydrocortisone. 
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3.4.2 Infrared Spectroscopy 
Figure 49 illustrates the infrared spectrum of the 50:50 PEG:hydrocortisone sample 
prepared using water as a pressure transmitting medium compared to PEG alone, 
hydrocortisone alone, the ambient 50:50 PEG:hydrocortisone ambient ballmilled 
sample and the water extracted from the pressure cell by ultra filtration. The 
spectrum of the pressurised sample is observed to be very similar to that of 
hydrocortisone, with the only difference being the presence of a 1096 cm-1 C-O-C 
peak. On investigation of the water solute sample, which was too fluorescent to 
undergo Raman spectroscopy, a prominent C-O-C peak was detected as well as the 
CH regions of 1457 and 1349 cm-1, and CO regions of 1252 and 1298 cm-1 present in 
PEG.  
 
Figure 50 illustrates the infrared spectrum of the 50:50 PEG:hydrocortisone sample 
prepared using petroleum ether as a pressure transmitting medium compared to PEG 
alone, hydrocortisone alone and the ambient 50:50 PEG:hydrocortisone ambient 
ballmilled sample. As the petroleum ether largely evaporates off there is no solute 
sample for this spectra. The pressurised sample spectrum is observed to be very 
similar to that of the ballmilled ambient sample, featuring both hydrocortisone and 
PEG regions. The large volume spectrum supports the Raman spectrum of this blend 
in that again it is much more comparable to the diamond anvil cell sample (Figure 
40) due to its more even ratio of PEG to hydrocortisone peaks.  
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Figure 49: Infrared spectra comparing the functional groups of the D) 50:50 
PEG:hydrocortisone large volume sample made using water as a pressure 
transmitting medium with that of the A) PEG, B) hydrocortisone, C) 
unpressurised sample and E) the water solute extracted from the pressurised 
sample.  
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Figure 50: Infrared spectra comparing the functional groups of the D) 50:50 
PEG:hydrocortisone large volume sample made using petroleum ether as a 
pressure transmitting medium with that of the A) PEG, B) hydrocortisone and C) 
unpressurised sample. 
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3.4.3 Drug Release Studies 
The advantage of scale up is unlike the needle loading method used for the diamond 
anvil cell, a more precise measurement of the drug added to the large scale cell can 
be made as the whole volume of the 50:50 PEG:hydrocortisone ballmilled sample 
can be added to the cell prior to pressure being applied. As the particle size achieved 
is greater it is also more forgiving in terms of distribution than the small scale 
diamond cell samples. The larger quantity of material also allows the removal and 
replacement of the whole 1ml of media at each time point reducing the time spent by 
the drug in stagnant media, reducing the risk of degradation of the drug.  
 
Drug release was carried out on large volume samples containing around 500ʅg of 
hydrocortisone in 1ml of simulated intestinal (Figure 51) or gastric fluids (Figure 
52). Initially looking at the samples in simulated intestinal fluids, a similar shape of 
drug release curve as Figure 46 can be observed, albeit with more of a sustained 
release character. Looking at the sample containing hydrocortisone derivatives in 
addition to the pure drug, in the first 8 hours release is relatively rapid with an 
average of 16% drug release being achieved. After this there is a period of sustained 
release until the 7 day mark with an average of around 7% drug release each day. On 
reaching the 7 day mark, an average of 62.52% drug release had been achieved. Over 
the following 3 days there is another immediate release burst, whereby an average of 
104.48% drug release is achieved. With hindsight the experiment may have needed 
an additional time point as the drug release curve is not entirely flat by 10 days. In 
the pure drug sample a similar pattern is observed, although the overall drug release 
is lower. The immediate release burst is observed to occur over 6 hours releasing 
8.94% and again there is a sustained release period until the 7 day mark but only 
40.96% is released by this point, with an average of 5.85% release per day. This is 
then followed by another immediate release burst which takes the release up to an 
average of 80.30%. It should be noted the error bars are slightly smaller than that of 
the diamond anvil cell samples. The standard error values are detailed in A3.2 of 
Appendix 3. The difference between the maximum release values were compared 
using an unpaired T-test, and were found not to be significant with a P-value of over 
0.05, at 0.18.  
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Figure 51: Drug release from 50:50 PEG:hydrocortisone large volume pressurised 
samples in simulated intestinal fluid, where n=3 for each and SE± the values 
given in A3.2 of Appendix 3. P>0.05 for the maximum release comparison of 
pure and derivative containing samples. 
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 Investigating the samples in simulated gastric fluid (Figure 52) a slightly different 
pattern is observed, with an additional step like feature in the curve. Initially, looking 
at the derivative containing sample, in the first 24 hours there is an immediate release 
burst in which an average of 32.37% drug release is achieved. Following this there is 
a delay in release of 24 hours where only 36.74% release is reached. There is then 
another burst of immediate release over the next 24 hours where release reaches an 
average of 62.64%. There is a sustained release period of 4 days after which 86.20% 
release is reached, with an average of 5.89% release per day. There is then a final 
immediate release burst reaching 116.47% drug release by the 10 day mark. Again an 
additional data point may have been required to fully level the curve off. Examining 
the pure sample, the pattern of a matching curve at lower percentage drug releases 
seen in the simulated intestinal fluid samples is mirrored in the simulated gastric 
fluid samples. Initially there is a burst of immediate release over the first 6 hours 
reaching 7.89% release, followed by a brief sustained release period culminating in 
the curve nearly levelling off, reaching 17.46% release by 48 hours. This is followed 
by another burst of immediate release over the next 24 hours reaching 39.32% drug 
release by 72 hours. There is then a sustained release period which continues until 
the 10 day point is reached at 79.53% release. The maximum values were compared 
via unpaired T-tests using OriginPro. There is not a significant difference between 
the samples as demonstrated by a P-value over 0.05, at 0.356. Again comparing the 
simulated intestinal fluid samples with the simulated gastric fluid samples, neither 
the pure samples nor the samples with derivatives were found to be significantly 
different with P-values of 0.982 and 0.577 respectively. The standard error values are 
detailed in A3.3 of Appendix 3. 
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Figure 52: Drug release from 50:50 PEG:hydrocortisone large volume pressurised 
samples in simulated gastric fluid, where n=3 for each and SE± the values given 
in A3.3 of Appendix 3. P>0.05 for the comparison of the maximum release of 
pure and derivative containing samples. 
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Chapter 4: Discussion 
 
The aim of this study was to investigate the effect of pressure on polyethyelene 
glycol to create an effective drug delivery system for poorly water soluble drugs, 
with a view to increase their bioavailability. 
 
4.1 PEG 
 
PEG was found to melt under high pressure conditions as marked by the flowing of 
the substance observed accompanied by the colour change from white to colourless 
by 5GPa. On removal of pressure the transparency is retained as the powder becomes 
a solid disk. This melting action is believed to be due to loss of the C-O-C second 
peak and the smoothing of the CH peak present in the Raman spectra, both of which 
could be attributed to the reduction in the population of the bond energies of 
PEG4000 on becoming molten. This change is then reversed on removal of the 
pressure, suggesting a return of the rigidity on solidifying. These changes are 
mirrored in the infrared spectroscopy with the greatest change being observed in the 
C-O-C peak as it is significantly diminished after pressure. 
 
Differential scanning calorimetry illustrated that PEG4000 melts over an average 
range of 58.67 to 63.61°C, with an average peak temperature of 61.73°C. Like the 
pressure treated samples, the infrared spectra taken of these samples showed a 
decrease in the size all the peaks compared to an ambient sample with the most 
considerable change occurring in the C-O-C peak, confirming that the same type of 
melt transition is generated by pressure as by the normal temperature method. 
Thermogravimetric analysis demonstrated that, on average, PEG degrades by 
96.53% between 335 and 445°C. 7KH GLVWLQFW WHPSHUDWXUH GLIIHUHQFH LQ 3(*¶V
melting range relative to the point at which it degrades is highly useful as it indicates 
it is stable at its melting point and does not degrade. Which due to the other 
similarities observed may suggest the similar reaction under high pressure is also not 
causing degradation.  
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Due to the pressure being observed to induce a solid to liquid phase change at 5GPa 
at room temperature and the temperature range 58.67 to 63.61°C at which PEG melts 
and is stable, as proven by differential scanning calorimetry and thermogravimetric 
analysis, it was hypothesised pressure could be used to reduce the temperature 
required to melt PEG.  This was proven via temperature versus pressure studies, 
which showed the two variables to be inversely proportional. There have been a 
number of studies carried out paring pressure and temperature using the diamond 
anvil cell techniques largely on crystals, but little has been studied on powders 
previously in this apparatus in combination with temperature (Shinoda and Noguchi, 
2008, Hazen and Finger, 1981). High pressure has been shown a means of melting 
polymers before, however previously work has been in polymers which tend to 
increase in melting point such as ethylene vinyl acetate copolymers, rather than 
reducing it (Seeger et al., 2004). As such this study is fairly novel. 
 
4.2 Hydrocortisone 
 
On application of pressure, the Raman spectra of hydrocortisone exhibit a smoothing 
and shift to a higher wavenumber of the peak of the aromatic CH functional group at 
2890 cm-1 as well as a merging of the 1611 cm-1 and 1644 cm-1 alkene peaks. These 
peaks correspond to the two C=C bonds present in two of the three polymorphs of 
hydrocortisone. Forms I and II require two molecules to describe the crystal structure 
and therefore there are two C=C functional groups per polymorph, where as form III 
only consists of one molecule and thus only one C=C functional group 
(Suitchmezian et al., 2007).  Therefore the hydrocortisone polymorph present in this 
study must be either form I or II. The alkene bond present in each molecule should 
have a similar energy but the packing effects exerted by the crystal structure causes 
the stretching frequencies to change in wavenumber slightly, as can be observed in 
Figure 30. As the pressure is applied to the crystalline structure the molecules receive 
different forces and therefore move at different rates. The change in the C=C region 
is supported by the infrared spectra. Due to the return of these peaks on return to 
ambient it is suggested that the changes in these peaks are not resulting in permanent 
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changes to the molecule, which can be confirmed by the differential scanning 
calorimetry results. 
 
The differential scanning calorimetry results suggest hydrocortisone on average 
melts over the temperature range of 223.49 and 228.15°C, with an extrapolated peak 
of 226.93°C.  Hydrocortisone can exist in three polymorphic forms. As this is a 
single endothermic peak, rather than two as exhibited by the Form III polymorph, it 
is suggested this batch of hydrocortisone is in fact Form I or Form II (Suitchmezian 
et al., 2007). The higher melting point does suggest it is Form I as a previous study 
showed an onset temperature for this to be 222ºC and an extrapolated peak 
temperature to be 225ºC, compared with an onset temperature of 220ºC and an 
extrapolated peak temperature of 222ºC for Form II, although due to changing 
conditions this cannot be said for certain (Suitchmezian et al., 2007). 
Thermogravimetric analysis reveals the melting range is very close to the 
degradation range, the start of which is exhibited by the presence of the colour 
FKDQJH WR \HOORZ RQ IRUPDWLRQ RI ȕɲ-dihydroxy-3,20-dione-4-pregnene-21-al. 
This results in a major increase in the size of the C=O and the CH infrared peaks. 
This is not observed in the pressurised samples and thus this degradation step is 
avoided. 
 
4.3 PEG + Drug 
 
The 50:50 PEG:hydrocortisone blend was investigated by Raman spectroscopy. PEG 
and hydrocortisone behave in the same manner as they did alone and PEG effectively 
entaps hydrocortisone. Differential scanning calorimetry revealed the melting point 
of PEG was unchanged by combination with hydrocortisone but PEG did have a 
shielding effect on hydrocortisone, lowering its melting point slightly. Thus it could 
be suggested due to the inversely proportional relationship of temperature and 
pressure that PEG still flows in the same manner in the presence of hydrocortisone as 
it does alone. The white to yellow colour change is still observed in the 
hydrocortisone in the DSC samples but not the pressurised samples further 
supporting the theory that hydrocortisone does not reach the level of degradation 
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under pressure as it does at the higher range of its relatively unstable temperature 
induced molten state, which is indicated by the thermogravimetric analysis.  
 
The 50:50 blend was chosen to take forward to drug release testing as this blend was 
thought to be most useful formulations have a high ratio of drug but due to the poor 
solubility of hydrocortisone this drug needs to be balanced with a sufficient level of 
PEG. Initially a drug release study on the diamond anvil cell particles was carried out 
in pH7.4 PBS with analysis by UV spectroscopy. Although this was not repeated due 
to issues with the UV equipment and also simulated fluids being deemed to have a 
better in vitro/in vivo correlation, Figure 45 shows the same pattern of drug release 
which was observed in later studies, with a period of immediate release followed by 
a period of sustained release and then another period of immediate release. 115.58% 
was released by 24 hours, which is slightly over the expected drug release, which 
may suggest there is an uneven distribution of drug in the sample. This can be 
attributed to there being such a small amount, mere micrograms, added to the 
pressure cell using a needle and no real way of being certain of the amount of each 
substance on that needle. 
 
After consideration of the studies, the diamond anvil cell samples were then studied 
in simulated intestinal and gastric fluids. The mass of drug expected to release in the 
1ml of fluid was 25ʅg as this was comparable to the standard dose of 25mg per day 
which in standard USP testing would be in 1L. So as such the 25ʅg/ml is directly 
comparable. The analysis method was changed from UV spectroscopy to HPLC due 
to issues with the equipment. HPLC was actually found to be more useful overall as, 
unlike UV analysis alone, it was able to reveal the substantial instability of 
hydrocortisone in aqueous solution. HPLC revealed that hydrocortisone was 
degrading in aqueous solutions, as once the drug release was analysed additional area 
under the curve peaks were found to be present close to the main drug peak. From 
the literature, these peaks were found to be hydrocortisone derivatives (Walters and 
Dunbar, 1982).  This formation of derivatives via degradation is supported by a 
number of previous studies.  
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Hydrocortisone has been shown previously to degrade under aqueous conditions. In a 
previous study looking at hydrocortisone in aqueous solutions, it was noted that an 
oxidative degradation resulting in the generation of 21-dehydrohydrocortisone which 
latterly broke down into a 17-carboxylic acid and a 17,20 dihydroxy-21-carboxylic 
acid derivative, and a non-oxidative reaction giving a 17-oxo, 17-deoxy-21-aldehyde 
and 17-deoxy-20-hydroxy-21-carboxylic acid derivative. Breakdown was almost 
entirely caused by reactions of the C17-dihydroxyacetone side chain. In 0.1M acetate 
buffer at pH5.07 the greatest degradation appears to be non-oxidation resulting in 17-
deoxy-21-dehydrohydrocortisone at 35% at its peak at 142 hours, although there is 
also some oxidative degradation of the aldehyde group resulting in 21- 
dehydrohydrocortisone formation at 10% at its peak of 113 hours. There is a drop in 
this to 5% at 142 hours. In 0.1M phosphate buffer at pH6.19 the opposite is observed 
with greater non-oxidative degradation, reaching 55% at 25 hours, and less oxidative 
degradation, reaching 10% at 25 hours (Hansen and Bundgaard, 1980). However this 
degradation can be decreased by addition of stabilising agents such as fructose 
(Bansal et al, 1983) or disodium edentate. The latter can be used to reduce oxidative 
degradation as it can prevent generation of 21-dehydro degradation products. The 
non-oxidative reaction seems to be triggered by highly acidic conditions as the non-
oxidative 17-deoxy steroid-glycox degradation products are formed in the presence 
of acidic conditions. Thus the use of enteric coatings to protect against the acidic 
gastric environment could be incorporated into a formulation to prevent this 
degradation (Hansen and Bundgaaard, 1980). This previous evidence supports the 
observed degradation and may suggest which products are being formed although 
further analysis of the media would be required to confirm this in the current sample. 
 
Taking into account these derivatives, in the first 30 minute immediate release burst, 
an average of 55.89% of the sample was released in simulated intestinal fluid. In the 
first 1 hour immediate release burst, an average of 54.02% of the sample was 
released in simulated gastric fluid. The sustained release period resulted in 72.77% 
and 62.25% release by 6 hours in simulated intestinal and gastric fluids respectively. 
An average of 111.4% and 107.88% release occurred by 8 hours in simulated 
intestinal and simulated gastric fluids respectively. Again this is over 100% which 
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does suggest, as in Figure 45, that there is an uneven distribution of drug in the 
samples which again can be attributed to the sample size and method of production. 
This can be supported by the size of the error bars. Although both sets of drug release 
have levelled off after 8 hours, the drug release is found at 24 hours to be in fact 
97.87% and 89.57% in simulated intestinal and gastric fluids respectively. This could 
be attributed to greater degradation of the hydrocortisone to a level which cannot be 
read by the HPLC. Although this may be due to problems with the HPLC method. 
The lack of disparity between the two pH values at their maxiumum does however 
suggest there is some level of pH independence to the system.  
 
Looking at the pure samples, the release in simulated intestinal fluid shows a similar 
pattern of release to the overall sample including derivatives, however only 12.24% 
release is achieved in the first immediate release burst and 41.84% after the second. 
Again after by the 24 hour time point there is a considerable drop in the release to 
24.15%, which may be attributed to further degradation. By 8 hours and 24 hours 
69.58% and 73.72% of the hydrocortisone released was lost to degradation 
respectively. Likewise the release in simulated gastric fluid there is considerably less 
release observed without taking the derivatives into account. After the first 
immediate release burst, only 11.38% release had been achieved and unlike the 
simulated intestinal fluid sample sustained release continues until 24 hours, with 
ultimately 28.54% release overall.  Thus there is only 18.70% release by 8 hours, 
which may suggest the acidity of the simulated gastric fluid causes greater 
degradation of hydrocortisone in the crucial first 8 hours than the less acidic 
simulated intestinal fluid. This is supported by the fact that by 8 hours and 24 hours 
89.18% and 61.03% of the hydrocortisone released was lost to degradation 
respectively. The uneven distribution can also be observed in these samples in the 
form of the error bars.  
 
The pattern of release observed in most of samples is quite comparable to standard 
oral dose regimens of hydrocortisone (Abad-Santos et al., 2002, Simon et al., 2010), 
but due to it being from a single administration it is possibly more comparable to a 
pulsatile system (Tangri and Khurana, 2011). The pulsatile nature of the system is 
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believed to stem from the fact the centre of the high pressure particles receives the 
greatest level of pressure from the combination of the diamonds and powder mass 
working together and thus may create a region which is less easily degraded relative 
to the more loosely pressurised periphery. This drug release pattern is quite 
significant as it actually mirrors conventional oral cortisol replacement regimens 
without the need for multiple dosing. This could be applicable to cortisol 
replacement therapy in paediatric and geriatric care, as these two groups tend to be 
more difficult to treat due to refusal of medication or forgetfulness (Gröschl et al., 
2002 and Nikolaus et al., 1996). The reduction of multiple dosing is also highly 
significant as multiple dosing often can result in overdosing or underdosing. The 
former can lead to toxic side effects and the latter can lead to break through 
symptoms (Nikolaus et al., 1996). 
 
Chan and Debono (2010) suggested a number of sustained and immediate release 
combinations which support the theory that the formulation could be adapted follow 
the circadian rhythm. However unlike the current formulation they suggest the 
addition of a delayed release period, which would mean adding an purely excipient 
layer outside the formulation as it stands to allow the patient self administer before 
sleeping and have a burst of hydrocortisone before waking. Johannsson et al. (2009) 
also suggest the use of an immediate release burst but they then employ a prolonged 
period of sustained release which may suggest a future modification to the current 
system.  
 
4.4 High Pressure Scale Up 
 
The 50:50 PEG:hydrocortisone blend was pressurised using a large volume press to 
investigate the capacity of this high pressure study for scale up. Due to the large 
volume press not being able to reach as high a pressure as the diamond anvil cell, 
temperature was employed to compensate, drawing on the previous evidence of the 
inversely proportional relationship between pressure and temperature. Due to the 
larger volume of substance the powder density could not be used to transmit the 
exerted pressure alone and as such a pressure transmitting medium was required. 
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Initially water was employed for this purpose. The Raman and infrared spectra 
(Figures 48 and 50) for the high pressure sample generated in this way illustrated an 
abnormally high content of hydrocortisone, which was not comparable to the spectra 
of the diamond anvil cell generated samples (Figures 38 and 41). The only influence 
of PEG which can be observed is that of the height seen in the CH region of the 
Raman (Figure 47) and the C-O-C region present in the infrared spectrum (Figure 
49). The rest of both spectra were nearly identical to the hydrocortisone spectra. The 
infrared spectrum was taken of the water filtered off the sample (Figure 49). Due to 
the high fluorescence of the solute sample, conferred by the hydrocortisone, the 
Raman spectrum could not be taken of this but as infrared is not affected by 
fluorescence, the infrared spectrum could be taken. The very prominent PEG C-O-C 
peak, CH peaks and CO peaks were observed in the spectrum of the water, 
suggesting that most of the PEG present in the sample originally had leached into the 
water due to its high aqueous solubility. 
 
Latterly the 50:50 PEG:hydrocortisone was pressurised utilising petroleum ether as a 
pressure transmitting medium, as this largely evaporates off after the pressure is 
removed (Figures 49 and 51). A more even distribution of PEG to hydrocortisone 
was observed with the CH region exhibiting a combination of the hydrocortisone and 
PEG ridges observed on the peak. The alkene peaks are also less prominent than they 
were in the water pressurised sample. PEG also has more of a role in the CH2 region. 
In the infrared, a more even distribution is also observed with both substances 
boasting a similar number of peaks each and neither substance overshadowing the 
other with OH, C=O, CH, C-O and =CH regions present for hydrocortisone and CH, 
C-O and C-O-C regions present for PEG4000. These factors in combination suggest 
the blend remains intact in this sample once the petroleum ether has evaporated off.  
 
Drug release was carried out on approximately 500ʅg of hydrocortisone, entapped 
within 50:50 PEG:hydrocortisone large volume press particles, in 1ml samples of 
simulated intestinal and gastric fluids (Figures 52 and 53). A different method of 
sample extraction was adopted for scale up as the concentration present in the 
solution was high enough that the removal and replacement of the 1ml whole 
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solution and calculation of the cumulative observed concentrations was feasible. It 
also reduced the time period that the drug was present in a stagnant aqueous solution 
prior to HPLC analysis in the hope less degradation would occur.  
 
Looking initially at the samples in simulated intestinal fluid, a similar immediate 
release, sustained release, immediate release pattern as that observed in Figure 46 
can be observed, although it does exhibit more of a sustained release character. An 
average of 16% release is achieved from the immediate release burst over the first 8 
hours, with an average of 8.94% of this burst being made up of pure hydrocortisone. 
An average of 62.52% release is achieved by the 7 day mark, following a period of 
sustained release, with an average of 40.96% being made up of pure hydrocortisone. 
The second immediate release burst allows a maximum mean release of 104.48%, 
with an average of 80.30% of this being made up of pure hydrocortisone. As there is 
only 24.18% lost to degradation by this final time point, compared to 73.72% lost by 
the final time point of the diamond anvil cell sample, the hypothesis that less 
degradation occurred on removal and replacement of the full 1ml of media was 
proven to be correct. Although the overall release is still over 100% the error bars are 
smaller than the ones corresponding to the diamond anvil cell samples, suggesting 
there is a more even distribution of drug in the large volume samples. With hindsight 
the author should have continued the study for another 24 hours to allow the curve to 
completely level off but this was not possible due to time constraints. 
 
Looking at the samples in simulated gastric fluid, there is a similar pattern again, but 
unlike previously there is a split in the initial immediate release burst, at 24 hours for 
the overall sample and 6 hours for the pure sample, where there is a delay in release 
until the 48 hour time point before the burst resumes tailing into the sustained release 
period at 72 hours, which culminates in another much more muted immediate release 
burst at the 7 day point, reaching its maximum at 10 days. For the overall sample, 
consisting of both pure hydrocortisone and its degradation products, there is an 
average of 116.47% release, which is slightly over 100% again, however the error 
bars are not as large as that of the diamond anvil cell samples so distribution is still 
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lost to degradation. This is slightly higher than the simulated intestinal fluid samples, 
which does suggest again the high acidity is resulting in greater degradation. 
However this is not as high a level as the diamond anvil cell samples and so again the 
removal and replacement of the full 1ml of media each time is reducing the period of 
exposure of the drug to the stagnant aqueous solution and thus reducing degradation. 
With hindsight the author should have continued the study for another 24 hours to 
allow the curve to completely level off but this was not possible due to time 
constraints. The difference in the SGF curves in comparison to the SIF curves, which 
are more comparable to both sets of diamond anvil cell samples, could be attributed 
WR K\GURFRUWLVRQH¶V DGKHVLYH VWLFN\ QDWXUH DV WKH VDPSOH WHQGHG WR VWLFN WR WKH
eppendorf wall.   
 
Overall the high volume studies were found to be relatively comparable to the 
diamond anvil cell studies in terms of the drug release pattern being independent of 
pH and the same immediate release, sustained release, immediate release pattern. 
However the large volume sample drug release released at a much slower rate.  Two 
considerations to make are a) the effect that the pressure-transmitting medium had on 
the large volume samples and b) the effect of hydrostatic versus non-hydrostatic 
medium. Both of these questions require further work to be carried out on this system 
giving thought to the requirement of having pressure transmitting medium for the 
large volume experiments. 
 
4.4 Future  
 
4.4.1 Formulation Changes 
Looking towards the future, the formulation could be modified for more efficient 
drug release and delivery. Different concentrations of drug could be explored more, 
for example taking forward the 80:20 PEG:hydrocortisone blend.  Due to the greater 
mass of the large volume samples release occurs over a much longer time period. 
This method of production, however, is more feasible on an industrial scale, as such 
the dose would need to be modified to a level which would give an overall release of 
25mg/L, possibly by altering the ratio of drug to polymer, although this would have 
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to be done with extreme care as there is a chance of making the system too soluble. 
Taking forward the 80:20 blend also may allow tailoring of the dose to the patient. 
Personalised medicine is a growing field and as previous evidence has shown cortisol 
is released at different levels in each individual, based on factors such as genetics or 
stress levels, this may be a potential area for exploration (Abad-Santos et al., 2001). 
 
The formulation also could be modified to include stabilising agents such as 
disodium edentate to withstand oxidative degradation or encased in an enteric 
coating to protect the drug against the acidic effects of the gastric fluid, which would 
normally generate non-oxidative degradation of hydrocortisone to allow the drug to 
reach the site of absorption intact (Hansen and Bundgaard, 1980, Tangri and 
Khurana, 2011).  
 
4.4.2 Applications 
The formulation could also be applied to a number of different functions as the 
pulsatile nature of the release pattern can be highly useful. Pulsatile systems are 
defined as drug delivery formulations with the capacity to release the drug at a 
specific area of the body and/or time via use of a combination of delayed release 
periods and immediate release periods, and they are usually formulated to fit a 
specific circadian rhythm (Rao et al., 2013).  
 
Pulsatile systems have been widely used previously for delivery of drugs such as 
peptic and duodenal ulceration, cardiovascular conditions, arthritis, asthma, diabetes, 
neurological conditions, cancer and hypercholesterolemia, as it is well documented 
as a method of targeting release and timing it to fit circadian rhythms (Tangri and 
Khurana, 2011). Diabetes mellitus can be treated orally using pulsatile systems be 
targeting the increase in glucose level in the fed state with sulfonylurea and 
biguanides such as metformin. Arthritis can be treated orally by targeting the 
circadian rhythm of the greatest pain on waking using pulsatile release of NSAIDs 
(Rao et al., 2013). Zolpidem has been shown to benefit from formulation with 
PEG4000 before and due to its purpose as an insomnia treatment it could be adapted 
in the current system for a pulsatile release by allowing a burst to allow the patient to 
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fall asleep and a further burst to keep the patient asleep, as many insomnia suffers 
tend to wake in the middle of the night (Trapani et al., 1999). As such the current 
system may be applied to some of these drugs. 
 
Pulsatile release is particularly useful for early morning or night time dosing and also 
for mimicking natural body functions which follow circadian rhythms such as release 
of hormones. As such in the case of the current study it could be tailored to release 
the drug at times mimicking cortisol release for patients with adrenal insufficiency 
(Tangri and Khurana, 2011, Simon et al. 2010, Johannsson et al.,2007, Chan and 
Debono, 2010).  
 
The advantage in the case of highly unstable drugs such as hydrocortisone it can be 
WDLORUHG WR UHOHDVH QHDU WKH GUXJ¶V DEVRUSWLRQ VLWH PLQLmising the time in the 
gastrointestinal fluid (Rao et al., 2013). A delayed release period can also be highly 
effective in preventing breakdown of drugs in the gastric acid of the stomach and are 
required to reach the intestine before absorption can occur. Equally so this delayed 
release period can reduce the effects of first pass metabolism (Tangri and Khurana, 
2011). The ability to target the drug also increases bioavailability, reduces the risk of 
overdosing through dose dumping and minimises toxicity and adverse effects (Rao et 
al., 2013). However, for the current study to progress the delivery system may need 
to be tested with other poorly soluble drugs. 
 
4.4.3 Other Drugs 
If the current study was to be taken forward the drug would have to be changed for 
another poorly soluble drug as the instability of hydrocortisone renders the system of 
little use in vivo. If the drug was replaced with a more stable agent the drug release 
would be more comparable to a suitable drug delivery system in vivo. The drug 
could be replaced with drugs such as the anti-arthritis agents prednisone and 
naproxen, or the bronchodilator and anti-inflammatory agent theophylline used in 
asthmatic patients (Barnes, 2010, Kirwan and Buttgereit, 2012). The pulsatile nature 
of the system may prove useful for these drugs as arthritis and asthma both operate 
under a circadian rhythm with these conditions being at their worst on waking 
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(Burioka et al., 2010, Kirwan and Buttgereit, 2012). Thus these drugs could be 
administered at night, releasing a burst of drug release prior to waking. A pulse prior 
to sleeping may also allow the patient to fall asleep without discomfort. Theophylline 
use within a pulsatile system has been previously documented as part of a swellable 
dosage form (Dashevsky and Mohamad, 2006). It is hoped with the use of a different 
drug, a better, smoother drug release profile could be achieved, potentially with less 
margin of error between samples and thus greater reliability due to the drug staying 
intact under aqueous conditions. This in turn may allow greater comparability to 
previous work. 
4.4.4 Other Polymers 
Although polyethylene glycol is one of the most commonly used polymers for drug 
delivery, it is by no means perfect. The increasing use of this polymer has revealed a 
number of problems. Hypersensitivity is a problem which occurs due to interactions 
between the polymer and the immune system. As early as the 1950s, polyethylene 
glycol was associated with embolisms due to severe blood clotting. Anaphylactic 
shock can also be triggered due to complement activation, for example through the 
negative effects of histamine and proinflammatory cytokine expression. There can 
also be gastrointestinal disturbances on oral administration. Cutaneous topical 
administration can cause skin allergies such as contact dermatitis (Knop et al., 2010).  
There is also evidence that it can potentially result in a worsening effect on the 
adverse effects of alcohol, as shown in rats in vivo (Cho et al., 1992). Changes in 
pharmacokinetic behaviour are another issue associated with polyethylene glycol. 
PEGylated liposomes and polyethylene glycol based micelles have been associated 
with enhanced blood clearance and thus potentially decreased bioavailability (Knop 
et al., 2010).  
 
Non-biodegradablility of polyethylene glycol is further problem which potentially 
could be overcome. Potentially using lower molecular weight polyethylene glycols 
could overcome this problem but below 400Da toxicity is exhibited by the polymers, 
due to its breakdown into diacid and hydroxyl acid metabolites (Veronese and Pasut, 
2005, Knop et al., 2010).  Conversely, degradation under stress is another issue with 
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polyethylene glycol. This can result during various procedures including simple flow 
of solutions, stirring or ultrasound treatment (Knop et al., 2010).   
 
There is also evidence it may potentially cause pancreatitis as seen in a 75 year old 
woman (Franga and Harris, 2000). Toxicity of side-products is also of great concern. 
The main bi-product of polyethylene glycol production is the cyclic dimer of 
ethylene glycol, 1,4-dioxane. This is of concern as it has been suggested to have 
carcinogenic effects, limiting the amount which can be present in a formulation to 
10ppm. Studies in mice have not shown this effect and as such it is still under debate 
in America. The polymer can also include ethylene glycol monomers which have not 
fully polymerized. This also has been associated with cancer (Knop et al., 2010). 
Excretion of polyethylene glycol can also cause problems. Like other polymers, it is 
normally removed from the body in the urine or faeces but high molecular weight 
polyethylene glycols can build up in the liver, resulting in macromolecular 
syndrome. The molecular weight can be reduced by decreasing the chain length via 
enzyme degradation by cytochrome P450 or alcohol dehydrogenase in the body. 
Toxic effects can occur if this does not happen (Veronese and Pasut, 2005).  
 
As a result of all these problems, there may be a need for alternative polymers. In the 
current study it is hoped further investigation can be carried out using chitosan, 
which is a polysacchaULGHFRQVLVWLQJRIOLQHDUȕ-4)-linked monosaccharides. It is 
PDGH XS RI ȕ -4)-2-acetamido-D-JOXFRVH DQG ȕ -4)-2-amino-D-glucose joined 
with glycosidic bonds (Wang et al., 2011). The primary peptide groups give chitosan 
characteristics, such as being a cation and possessing mucoadhesive properties, 
which can be utilised in drug delivery. Chitosan is acquired from the formation of a 
peptide group from an acetamide group in chitin. Chitin is a chemically inactive 
polysaccharide found in the shells of marine crustaceans such as lobsters, shrimp and 
crabs. Formation of chitosan is achieved by exposure of chitin to alkaline conditions 
causing deacetylation. As it is derived from a substance isolated from a living 
creature it possesses a good level of biocompatibility which is highly advantageous 
in a drug delivery system. It is also cheap to produce as its origin is naturally 
occurring and relatively abundant. Chitosan is fairly reactive and utilised at 
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molecular weights from 3800 to 20,000Da. It can be utilised in powder, paste, film, 
fibre and other states (Agnihotri et al., 2004). Chitosan can exist in a number of 
forms, as the number of primary peptide groups in the polymer main chain and the 
molecular weight of this polymer can vary considerably. This variation primarily 
arises from the reaction circumstances involved in the production of chitosan from 
chitin. A typical batch of chitosan on the market has about 66-95% primary amine 
groups in the polymer main chain (Sonia and Sharma, 2011). As such chitosan 
polymorphism could prove an interesting area of research. 
 
The advantage of chitosan over polyethylene glycol is that it degrades into 
glycosylated amines, which the body can absorb and treat like peptides and sugars 
obtained from food. As such the risk of toxicity and thus adverse effects is 
significantly less (Agnihotri et al., 2004). One disadvantage chitosan has is in many 
cases it only dissolves in more acidic conditions and thus release from a chitosan 
based oral delivery system would either occur in the stomach or would require 
additional disintegrants (Agnihotri et al., 2003). This means chitosan has a number of 
applications in gastroretention, examples of which are detailed below. However there 
are some instances in which solubility is improved to give a better range of oral drug 
delivery applications. The degree of deacetylation chitosan undergoes in its 
production from chitin can have an impact as those with 40% deacetylation or less 
are capable of dissolution in substances up to pH 9, however those with 85% 
deacetylation or more fail to dissolve over pH6.5. This solubility effect is due to salt 
formation at lower degrees of deacetylation (Hejazi and Amiji, 2003). This would 
allow release to occur in the intestines, giving a broader range of drugs which may be 
used with chitosan. To allow dissolution at a neutral pH N-trimethylated and N-
triethylated oligosaccharide forms of the polymer have also been generated. Thus 
although it is primarily used for mucoadhesive and gastroretentive applications, it is 
becoming easier to use it in other oral formulations (Agnihotri et al., 2004). 
 
Chitosan has previously been shown to be effective in enhancing the solubility of 
poorly soluble drugs. For example griseofulvin can be effectively emulsified in 
chitosan microparticles (Agnihotri et al., 2004). Low molecular weight chitosan can 
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increase water solubility of oral formulations such as that of docetaxel, insulin and 
paclitaxel (Markovsky et al., 2012). Chitosan paclitacel conjugates have also been 
effectively formulated using a biodegradable succinate linker. Cyclosporin A was 
encapsulated in chitosan nanoparticles for use in eyedrops (Hu et al., 2013). For 
poorly soluble acidic agents, including indomethecin, the anionic nature of the drug 
can interact with the cationic nature of the polymer to form a gel, allowing controlled 
release to occur. More rapid release of the drug can occur in the colon due to the 
increase in pH enhancing the gelling effect which is initially evoked in the acidic 
environment of the stomach (Illum, 1998). Chitosan has been effectively used for a 
gastroretentive drug formulation using the poorly soluble drug verapamil, using both 
mucoadhesive properties and the ability to float on the gastric fluid (Sonia and 
Sharma, 2011). 
 
4.7 Conclusions  
 
Ultimately, PEG4000 was shown to effectively melt at high pressure transitioning 
fully from a solid to a liquid state at 5GPa. Hydrocortisone does not melt under 
pressure or physically change and thus could be effectively encapsulated in the PEG 
at high pressure. Drug release was observed to occur from the diamond anvil cell 
samples in simulated intestinal and gastric fluids over 8 hours in a pulsatile fashion, 
mimicking traditional cortisol replacement therapy but with one administration rather 
than multiple administrations daily. The establishment of the inversely proportional 
relationship of temperature and pressure for the solid to liquid phase transition of 
PEG allowed the investigation of scale up. Due to the greater mass of drug utilised 
drug release occurred over 10 days in a similar pulsatile fashion to the small volume 
study. Unfortunately due to the highly unstable nature of hydrocortisone in aqueous 
solutions future work would have to consider the use of stabilisers such as fructose or 
disodium edentate, or carry out studies on a different drug as the pulsatile character 
of the system could be applied to a number of drugs for conditions exhibiting a 
circadian rhythm. Overall PEG does increase the solubility of poorly soluble drugs 
but further work could be carried out in terms of formulation. 
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Appendices 
Appendix 1: 90:10 PEG:Hydrocortisone Pressure Studies 
 A1.1: Raman spectra of the 90:10 PEG:hydrocortisone blend illustrating the effect of  
increasing pressure. 
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A1.2: Raman spectra of the C-O-C region of the 90:10 PEG:hydrocortisone blend 
illustrating the effect of increasing pressure. 
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A1.3: Raman spectrum of the 90:10 PEG:hydrocortisone blend C-O-C region after 
pressure removal. 
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 A1.4: Raman spectra showing the effect of pressure removal on the 90:10 
PEG:hydrocortisone blend, illustrating A) the blend at ambient pressure, B) at 5GPa 
and C) after pressure removal. 
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A1.5: Infrared spectra of the 90:10 PEG:hydrocortisone blend illustrating the effect 
of pressure by comparison of the sample A) under ambient conditions and B) after 
pressure. 
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 PEG  
 
Hydrocortisone 
Sample Onset 
(°C) 
Extrapolated 
peak (°C) 
Endset  
(°C) 
Onset 
(°C) 
Extrapolated 
Peak (°C) 
Endset  
(°C) 
1 58.30 61.28 63.57 167.73 168.48 173.24 
2 58.08 61.31 62.81 168.49 168.83 173.01 
3 58.03 61.69 63.30 166.80 169.20 172.95 
Average 58.14 61.43 63.23 167.67 168.84 173.07 
S.E. 0.082932 0.131951 0.222436 0.488683 0.207873 0.08838 
 
A1.7: Differential scanning calorimetry of 3 replicates of 90:10 
PEG:hydrocortisone, with the mean onset, extrapolated peak and endset 
temperatures. 
A1.6: Differential scanning calorimetry of the 90:10 PEG:hydrocortisone sample, 
showing the melting points for PEG and hydrocortisone. 
Temperature (°C) 
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A1.8: Infrared spectra illustrating the effect of DSC treatment on the functional 
groups of 90:10 PEG:hydrocortisone samples by comparing the spectra A) before 
and B) after DSC treatment. 
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Sample Approximate 
Temperature 
Range (°C) 
Percentage 
degradation (%) 
1 200-460 95.3823 
2 200-465 95.1172 
3 215-455 93.2281 
Average 205-460 94.58 
S.E. 5 and 
2.888751 
0.678215 
 
A1.9: Thermogravimetric analyis of the 90:10 PEG:hydrocortisone sample, 
showing the percentage degradation. 
A1.10: Thermogravimetric analysis of 3 replicates of 90:10 PEG:hydrocortisone, 
giving the mean percentage degradation. 
Temperature (°C) 
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Appendix 2: 80:20 PEG:Hydrocortisone Pressure Studies 
 
  
A2.1: Raman spectra of the 90:10 PEG:hydrocortisone blend illustrating the effect of  
increasing pressure. 
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A2.2: Raman spectra of the C-O-C region of the 90:10 PEG:hydrocortisone blend 
illustrating the effect of  increasing pressure. 
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A2.3: Infrared spectra of the 90:10 PEG:hydrocortisone blend illustrating the effect 
of  increasing pressure, comparing the sample at A) ambient and B) after pressure. 
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 PEG Hydrocortisone 
Sample Onset 
(°C) 
Extrapolated 
Peak (°C) 
Endset  
(°C) 
Onset 
(°C) 
Extrapolated 
Peak (°C) 
Endset  
(°C) 
1 57.92 60.82 63.06 184.10 189.49 193.46 
2 58.32 61.22 63.03 187.01 187.11 193.00 
3 58.14 61.21 63.70 187.66 189.45 192.76 
Average 58.13 61.08 63.26 186.26 188.68 193.07 
S.E. 0.115662 0.131698 0.218505 1.094537 0.786751 0.205372 
A2.5: Differential scanning calorimetry of 3 replicates of 80:20 
PEG:hydrocortisone, with the mean onset, extrapolated peak and endset 
temperatures. 
 
A2.4: Differential scanning calorimetry of the 80:20 PEG:hydrocortisone sample, 
showing the melting points for PEG and hydrocortisone. 
Temperature (°C) 
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A2.6: Infrared spectra of the 80:20 PEG:hydrocortisone blend illustrating the effect 
of  DSC treatment, by comparison of the sample A) at ambient and B) after DSC. 
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Sample Approximate 
Temperature 
Range (°C) 
Percentage 
degradation (%) 
1 205-460 91.2005 
2 210-470 91.8904 
3 205-465 91.1186 
Average 205.67-465 91.40 
S.E. 1.67 and 
2.886751 
0.244761 
 
A2.8: Thermogravimetric analysis of 3 replicates of 80:20 PEG:hydrocortisone, 
giving the mean percentage degradation. 
 
A2.7: Thermogravimetric analysis of the 80:20 PEG:hydrocortisone sample, 
showing the percentage degradation. 
Temperature (°C) 
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Appendix 3: 50:50 PEG:Hydrocortisone Drug Release 
 
A3.1: Standard Error (±) of Drug Release from Diamond Anvil Cell Generated 
Samples as Illustrated by Error Bars in Figure 46 
 
Time (h) 
Simulated Intestinal Fluid  
(% Drug Release) 
Simulated Gastric Fluid  
(% Drug Release) 
 
 
Pure  
Hydrocortisone 
Hydrocortisone 
with Derivatives 
Pure 
Hydrocortisone 
Hydrocortisone 
with Derivatives 
0 0 0 0 0 
0.255 1.63 9.50 1.48 1.59 
0.5 1.81 10.58 1.67 4.12 
1 1.60 12.51 2.14 12.55 
2 1.63 12.11 1.95 11.13 
3 3.92 12.58 2.18 16.30 
4 2.29 14.44 2.67 16.94 
5 2.71 17.29 2.31 11.96 
6 3.22 13.17 3.20 15.56 
7 8.34 17.41 2.79 14.89 
8 11.05 12.26 4.69 2.73 
24 3.12 21.02 7.75 17.96 
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A3.2: Standard Error (±) of Drug Release in Simulated Intestinal Fluid from Pressure 
Scale Up as Illustrated by Error Bars in Figure 51 
 
Time (h) 
Pure Hydrocortisone  
(% Drug Release) 
Hydrocortisone with Derivatives  
(% Drug Release) 
0 0  0  
0.25 0.16 0.18 
0.5 0.18 0.22 
1 1.09  1.20 
2 1.24 1.37 
3 1.35 1.53 
4 1.62 1.95 
5 1.76 2.00 
6 1.89 2.12 
7 1.90 2.19 
8 2.20 2.46 
24 1.00 2.39 
48 4.88 6.31 
72 7.48 8.79 
168 14.06 13.43 
216 9.64 5.03 
240 10.12 5.57 
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A3.3: Standard Error (±) of Drug Release in Simulated Gastric Fluid from Pressure 
Scale Up as Illustrated by Error Bars in Figure 52 
 
Time (h) 
Pure Hydrocortisone  
(% Drug Release) 
Hydrocortisone with Derivatives  
(% Drug Release) 
0 0 0 
0.25 0.07 0.16 
0.5 0.14 0.22 
1 0.15 0.47 
2 0.33 0.69 
3 0.52 0.79 
4 0.73 0.93 
5 0.91 1.18 
6 1.10 1.36 
7 1.16 1.54 
8 1.23 1.71 
24 3.16 11.58 
48 3.27 11.95 
72 11.29 6.87 
168 22.10 14.89 
216 27.88 17.79 
240 28.64 17.93 
 
